question,language,translated_query,multilingual_chunks,translation_chunks,multilingual_english,translation_english,multilingual_content,translation_content,system_prompt,multilingual_response,translation_response,multilingual_time,translation_time,retrieval_time_multi,retrieval_time_trans,generation_time_multi,generation_time_trans,llm_model,use_claude
इंसुलिन प्रतिरोध क्या है और यह कोशिकाओं में ग्लूकोज के प्रवेश को कैसे प्रभावित करता है?,hindi,What is insulin resistance and how does it affect glucose entry into cells?,". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insulin, and your blood glucose levels rise. You are at higher risk of developing type 2 diabetes if you: Many people with type 2 diabetes have no symptoms at all. If you do have them, the symptoms develop slowly over several years. They might be so mild that you do not notice them. The symptoms can include: Your health care provider will use blood tests to diagnose type 2 diabetes. The blood tests include: Treatment for type 2 diabetes involves managing your blood sugar levels. Many people are able to do this by living a healthy lifestyle. Some people may also need to take medicine: You can take steps to helppreventor delay type 2 diabetes by losing weight if you are overweight, eating fewer calories, and being more physically active

Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. If you have diabetes, your body doesn't make enough insulin or doesn't use insulin well. The glucose then stays in your blood and not enough goes into your cells. Over time, having too much glucose in your blood can causehealth problems. But you can take steps to manage your diabetes and try to prevent these health problems. Type 2 diabetes may be caused by a combination of factors: Type 2 diabetes usually starts with insulin resistance. This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is ahormonemade by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy. If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead toserious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems

Summary: If you havediabetes, your blood glucose, orblood sugar, levels are too high. Glucose comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. Withtype 1 diabetes, your body does not make insulin. Withtype 2 diabetes, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. Over time, having too much glucose in your blood can cause complications, including: If you have diabetes, you need to watch out for blood glucose levels that aretoo high(hyperglycemia) ortoo low for you(hypoglycemia). These can happen quickly and can become dangerous. Some of the causes include having another illness or infection and certain medicines. They can also happen if you don't get the right amount ofdiabetes medicines. To try to prevent these problems, make sure to take your diabetes medicines correctly, follow yourdiabetic diet, and check your blood glucose regularly",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insulin, and your blood glucose levels rise. You are at higher risk of developing type 2 diabetes if you: Many people with type 2 diabetes have no symptoms at all. If you do have them, the symptoms develop slowly over several years. They might be so mild that you do not notice them. The symptoms can include: Your health care provider will use blood tests to diagnose type 2 diabetes. The blood tests include: Treatment for type 2 diabetes involves managing your blood sugar levels. Many people are able to do this by living a healthy lifestyle. Some people may also need to take medicine: You can take steps to helppreventor delay type 2 diabetes by losing weight if you are overweight, eating fewer calories, and being more physically active

Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. If you have diabetes, your body doesn't make enough insulin or doesn't use insulin well. The glucose then stays in your blood and not enough goes into your cells. Over time, having too much glucose in your blood can causehealth problems. But you can take steps to manage your diabetes and try to prevent these health problems. Type 2 diabetes may be caused by a combination of factors: Type 2 diabetes usually starts with insulin resistance. This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is ahormonemade by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy. If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead toserious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems

Summary: If you havediabetes, your blood glucose, orblood sugar, levels are too high. Glucose comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. Withtype 1 diabetes, your body does not make insulin. Withtype 2 diabetes, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. Over time, having too much glucose in your blood can cause complications, including: If you have diabetes, you need to watch out for blood glucose levels that aretoo high(hyperglycemia) ortoo low for you(hypoglycemia). These can happen quickly and can become dangerous. Some of the causes include having another illness or infection and certain medicines. They can also happen if you don't get the right amount ofdiabetes medicines. To try to prevent these problems, make sure to take your diabetes medicines correctly, follow yourdiabetic diet, and check your blood glucose regularly","Insulin resistance is a condition in which your cells do not respond normally to insulin.

**Insulin resistance affects glucose entry into cells in the following ways:**

1. **Lack of response of cells**: When cells do not respond normally to insulin, glucose is unable to enter the cells.

2. **More insulin required**: As a result, your body requires more insulin to allow glucose to enter cells.

3. **Initial response**: At first your body makes more insulin to respond to the cells.

4. **Long-term effects**: But over time, your body doesn't make enough insulin, and you","Based on the provided medical information, insulin resistance is a condition in which your cells don't respond normally to insulin.

**How it affects glucose entry into cells:**

When you have insulin resistance, your cells fail to respond properly to insulin signals. Since insulin's job is to help glucose move from your bloodstream into your cells (where it can be used for energy), this resistance creates a problem:

1. **Glucose can't enter cells efficiently** - Without the normal insulin response, glucose has difficulty getting into your cells where it's needed for energy

2. **Your body compensates by making more insulin** - At first, your pancreas tries to overcome this resistance by producing extra insulin to force the glucose into cells

3. **Eventually, insulin production can't keep up** - Over time, your body may not be able to make enough insulin to compensate for the resistance, leading to rising blood glucose levels

4. **Glucose accumulates in the blood** - Since the glucose can't efficiently enter cells, it stays in your bloodstream, causing high blood sugar levels

This process is typically how type 2 diabetes begins. Insulin resistance is often the first step, and it may be caused by a combination of factors including being overweight and physical inactivity.",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to t
---
. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insu
---
Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin he
---
Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make gluco
---
Summary: If you havediabetes, your blood glucose, orblood sugar, levels are too high. Glucose comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them ",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to t
---
. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insu
---
Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin he
---
Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make gluco
---
Summary: If you havediabetes, your blood glucose, orblood sugar, levels are too high. Glucose comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them ",Healthcare assistant prompt,"इंसुलिन प्रतिरोध एक ऐसी स्थिति है जिसमें आपकी कोशिकाएं इंसुलिन के प्रति सामान्य रूप से प्रतिक्रिया नहीं करती हैं।

**इंसुलिन प्रतिरोध कोशिकाओं में ग्लूकोज के प्रवेश को इस प्रकार प्रभावित करता है:**

1. **कोशिकाओं की प्रतिक्रिया में कमी**: जब कोशिकाएं इंसुलिन के प्रति सामान्य रूप से प्रतिक्रिया नहीं करती हैं, तो ग्लूकोज कोशिकाओं में प्रवेश नहीं कर पाता।

2. **अधिक इंसुलिन की आवश्यकता**: इसके परिणामस्वरूप, आपके शरीर को ग्लूकोज को कोशिकाओं में प्रवेश कराने के लिए अधिक इंसुलिन की आवश्यकता होती है।

3. **शुरुआती प्रतिक्रिया**: पहले तो आपका शरीर कोशिकाओं को प्रतिक्रिया देने के लिए अधिक इंसुलिन बनाता है।

4. **दीर्घकालिक प्रभाव**: लेकिन समय के साथ, आपका शरीर पर्याप्त इंसुलिन नहीं बना पाता, और आप","प्रदान की गई चिकित्सा जानकारी के आधार पर, इंसुलिन प्रतिरोध एक ऐसी स्थिति है जिसमें आपकी कोशिकाएं इंसुलिन के प्रति सामान्य रूप से प्रतिक्रिया नहीं करती हैं।

**यह कोशिकाओं में ग्लूकोज के प्रवेश को कैसे प्रभावित करता है:**

जब आपके पास इंसुलिन प्रतिरोध होता है, तो आपकी कोशिकाएं इंसुलिन संकेतों पर ठीक से प्रतिक्रिया करने में विफल हो जाती हैं। चूँकि इंसुलिन का काम ग्लूकोज को आपके रक्तप्रवाह से आपकी कोशिकाओं में ले जाने में मदद करना है (जहाँ इसका उपयोग ऊर्जा के लिए किया जा सकता है), यह प्रतिरोध एक समस्या पैदा करता है:

1. **ग्लूकोज कोशिकाओं में कुशलता से प्रवेश नहीं कर सकता** - सामान्य इंसुलिन प्रतिक्रिया के बिना, ग्लूकोज को आपकी कोशिकाओं में प्रवेश करने में कठिनाई होती है जहां ऊर्जा के लिए इसकी आवश्यकता होती है

2. **आपका शरीर अधिक इंसुलिन बनाकर क्षतिपूर्ति करता है** - सबसे पहले, आपका अग्न्याशय कोशिकाओं में ग्लूकोज को मजबूर करने के लिए अतिरिक्त इंसुलिन का उत्पादन करके इस प्रतिरोध को दूर करने की कोशिश करता है

3. **आखिरकार, इंसुलिन का उत्पादन जारी नहीं रह पाता** - समय के साथ, आपका शरीर प्रतिरोध की भरपाई के लिए पर्याप्त इंसुलिन बनाने में सक्षम नहीं हो सकता है, जिससे रक्त शर्करा का स्तर बढ़ जाता है

4. **ग्लूकोज रक्त में जमा हो जाता है** - चूंकि ग्लूकोज कुशलता से कोशिकाओं में प्रवेश नहीं कर पाता है, इसलिए यह आपके रक्तप्रवाह में रहता है, जिससे रक्त शर्करा का स्तर बढ़ जाता है

यह प्रक्रिया आम तौर पर टाइप 2 मधुमेह की शुरुआत होती है। इंसुलिन प्रतिरोध अक्सर पहला कदम होता है, और यह अधिक वजन और शारीरिक निष्क्रियता सहित कई कारकों के संयोजन के कारण हो सकता है।",10.533942937850952,10.387609004974365,0.5299794673919678,0.5400841236114502,10.003963470458984,9.847524881362915,claude-sonnet-4-5-20250929,True
हृदय रोग के जोखिम पर पारिवारिक इतिहास का क्या प्रभाव पड़ता है?,hindi,What effect does family history have on heart disease risk?,". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use

WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use","Family history has a significant impact on heart disease risk:

**Impact of family history:**

1. **Family history of early heart disease** increases your risk

2. **Especially high risk** occurs when:
   - Your father or brother has been diagnosed with heart disease before the age of 55
   - Your mother or sister was diagnosed with heart disease before the age of 65

3. **Genetic Factors:** Research has shown that certain genes are associated with a higher risk of certain heart diseases

**Important point:**

Family history is a risk factor you **cannot change**. However, if you have a family history of heart disease, you can reduce your overall risk by controlling other risk factors, such as:
- eating a healthy diet
- exercising regularly
- don't smoke","Based on the provided medical information, family history has a significant effect on heart disease risk:

**Increased Risk with Family History:**
A family history of early heart disease raises your risk of developing heart disease. Specifically, you have a greater risk if you have a close family member who had heart disease at an early age:

- **Your father or brother was diagnosed before age 55**
- **Your mother or sister was diagnosed before age 65**

**Genetic Component:**
Research has shown that some genes are linked to a higher risk of certain heart diseases, which explains why heart disease can run in families.

**Important Note:**
Family history and genetics are risk factors that **you cannot change**. However, the information emphasizes that there are many other heart disease risk factors that you can modify through lifestyle changes, such as diet, physical activity, smoking cessation, and stress management. Making these changeable improvements can help protect your heart and improve your overall health, even if you have a family history of heart disease.",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors ma
---
WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors ma",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may 
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may ",Healthcare assistant prompt,"पारिवारिक इतिहास हृदय रोग के जोखिम पर महत्वपूर्ण प्रभाव डालता है:

**पारिवारिक इतिहास का प्रभाव:**

1. **प्रारंभिक हृदय रोग का पारिवारिक इतिहास** आपके जोखिम को बढ़ाता है

2. **विशेष रूप से उच्च जोखिम** तब होता है जब:
   - आपके पिता या भाई को 55 वर्ष की आयु से पहले हृदय रोग का निदान हुआ हो
   - आपकी माता या बहन को 65 वर्ष की आयु से पहले हृदय रोग का निदान हुआ हो

3. **आनुवंशिक कारक:** शोध से पता चला है कि कुछ जीन कुछ हृदय रोगों के उच्च जोखिम से जुड़े हैं

**महत्वपूर्ण बात:**

पारिवारिक इतिहास एक ऐसा जोखिम कारक है जिसे आप **बदल नहीं सकते**। हालांकि, यदि आपके परिवार में हृदय रोग का इतिहास है, तो आप अन्य जोखिम कारकों को नियंत्रित करके अपने समग्र जोखिम को कम कर सकते हैं, जैसे:
- स्वस्थ आहार लेना
- नियमित व्यायाम करना
- धूम्रपान न कर","प्रदान की गई चिकित्सा जानकारी के आधार पर, पारिवारिक इतिहास का हृदय रोग के जोखिम पर महत्वपूर्ण प्रभाव पड़ता है:

**पारिवारिक इतिहास से बढ़ा जोखिम:**
प्रारंभिक हृदय रोग का पारिवारिक इतिहास आपके हृदय रोग के विकास के जोखिम को बढ़ा देता है। विशेष रूप से, यदि आपके परिवार के किसी करीबी सदस्य को कम उम्र में हृदय रोग हुआ है तो आपको अधिक जोखिम है:

- **आपके पिता या भाई का निदान 55 वर्ष की आयु से पहले हुआ था**
- **आपकी माँ या बहन का निदान 65 वर्ष की आयु से पहले हुआ था**

**आनुवंशिक घटक:**
शोध से पता चला है कि कुछ जीन कुछ हृदय रोगों के उच्च जोखिम से जुड़े होते हैं, जो बताता है कि हृदय रोग परिवारों में क्यों चल सकता है।

**महत्वपूर्ण नोट:**
पारिवारिक इतिहास और आनुवंशिकी ऐसे जोखिम कारक हैं जिन्हें **आप बदल नहीं सकते**। हालाँकि, जानकारी इस बात पर जोर देती है कि कई अन्य हृदय रोग जोखिम कारक हैं जिन्हें आप जीवनशैली में बदलाव के माध्यम से संशोधित कर सकते हैं, जैसे कि आहार, शारीरिक गतिविधि, धूम्रपान बंद करना और तनाव प्रबंधन। इन परिवर्तनशील सुधारों को करने से आपके दिल की रक्षा करने और आपके समग्र स्वास्थ्य में सुधार करने में मदद मिल सकती है, भले ही आपके परिवार में हृदय रोग का इतिहास हो।",70.4241054058075,8.812736749649048,0.030982017517089844,0.5116298198699951,70.3931233882904,8.301106929779053,claude-sonnet-4-5-20250929,True
धूम्रपान का रक्तचाप और हृदय रोग के जोखिम पर क्या प्रभाव पड़ता है?,hindi,What effect does smoking have on blood pressure and heart disease risk?,". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure. Then you may need to take medicine. There are different types of blood pressure medicines. Some people need to take more than one type. If your high blood pressure is caused by another medical condition or medicine, treating that condition or stopping the medicine may lower your blood pressure. NIH: National Heart, Lung, and Blood Institute

. The risk of hypertension is increased if bupropion is used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity [see Contraindications (4) ] . Data from a comparative trial of the sustained-release formulation of bupropion HCl, nicotine transdermal system (NTS), the combination of sustained-release bupropion plus NTS, and placebo as an aid to smoking cessation suggest a higher incidence of treatment-emergent hypertension in patients treated with the combination of sustained-release bupropion and NTS. In this trial, 6.1% of subjects treated with the combination of sustained-release bupropion and NTS had treatment-emergent hypertension compared to 2.5%, 1.6%, and 3.1% of subjects treated with sustained-release bupropion, NTS, and placebo, respectively. The majority of these subjects had evidence of pre-existing hypertension","Smoking has the following effects on blood pressure and heart disease risk:

**Effect on blood pressure:**
- Smoking cigarettes increases your blood pressure

**Effect on heart disease risk:**
- Smoking increases the risk of heart disease
- It increases the risk of heart attack and stroke
- Smoking increases the risk of serious cardiovascular events
-This risk increases with age, especially in women over 35 years of age
This risk increases as the number of cigarettes smoked increases.

**Other risks:**
- Smoking is also a risk factor for venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism.

**Advice:**
If you don't smoke, don't start. If you smoke","Based on the provided medical information, smoking has significant negative effects on blood pressure and heart disease risk:

**Effects on Blood Pressure:**
- Cigarette smoking raises your blood pressure

**Effects on Heart Disease Risk:**
- Smoking puts you at higher risk of heart attack and stroke
- Stress combined with smoking (as a coping mechanism) is particularly harmful to the heart
- Smoking is linked to heart disease through multiple pathways

**Benefits of Quitting:**
- If you quit smoking, it will lower your risk of heart disease
- Smoking cessation is recognized as an important part of comprehensive cardiovascular risk management

**Medical Recommendation:**
The medical guidance is clear:
- If you do not smoke, don't start
- If you do smoke, quitting is strongly recommended
- Healthcare providers can help find the best method for you to quit

Smoking cessation is consistently mentioned alongside other cardiovascular risk management strategies such as blood pressure control, lipid control, diabetes management, exercise, and limited sodium intake as essential components of heart disease prevention.",". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure
---
. The risk of hypertension is increased if bupropion is used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity [see Contraindications (4) ] . Data from a com",Healthcare assistant prompt,"धूम्रपान का रक्तचाप और हृदय रोग के जोखिम पर निम्नलिखित प्रभाव पड़ता है:

**रक्तचाप पर प्रभाव:**
- सिगरेट पीने से आपका रक्तचाप बढ़ता है

**हृदय रोग के जोखिम पर प्रभाव:**
- धूम्रपान से हृदय रोग का खतरा बढ़ जाता है
- यह दिल के दौरे (heart attack) और स्ट्रोक का जोखिम बढ़ाता है
- धूम्रपान गंभीर हृदय संबंधी घटनाओं (cardiovascular events) का खतरा बढ़ाता है
- यह जोखिम उम्र के साथ बढ़ता है, विशेष रूप से 35 वर्ष से अधिक उम्र की महिलाओं में
- पीने वाली सिगरेट की संख्या बढ़ने के साथ यह जोखिम और भी बढ़ता है

**अन्य जोखिम:**
- धूम्रपान शिरापरक घनास्त्रता (venous thromboembolism - VTE) का भी जोखिम कारक है, जिसमें गहरी शिरा घनास्त्रता और फुफ्फुसीय अन्त: शल्यता शामिल हैं

**सलाह:**
यदि आप धूम्रपान नहीं करते हैं, तो शुरू न करें। यदि आप धू","प्रदान की गई चिकित्सीय जानकारी के आधार पर, धूम्रपान का रक्तचाप और हृदय रोग के जोखिम पर महत्वपूर्ण नकारात्मक प्रभाव पड़ता है:

**रक्तचाप पर प्रभाव:**
- सिगरेट पीने से आपका रक्तचाप बढ़ जाता है

**हृदय रोग के जोखिम पर प्रभाव:**
- धूम्रपान से आपको दिल का दौरा और स्ट्रोक का खतरा अधिक होता है
- धूम्रपान के साथ संयुक्त तनाव (मुकाबला तंत्र के रूप में) हृदय के लिए विशेष रूप से हानिकारक है
- धूम्रपान कई तरीकों से हृदय रोग से जुड़ा हुआ है

**छोड़ने के लाभ:**
- यदि आप धूम्रपान छोड़ देते हैं, तो इससे हृदय रोग का खतरा कम हो जाएगा
- धूम्रपान बंद करना व्यापक हृदय जोखिम प्रबंधन का एक महत्वपूर्ण हिस्सा माना जाता है

**चिकित्सा अनुशंसा:**
चिकित्सा मार्गदर्शन स्पष्ट है:
- यदि आप धूम्रपान नहीं करते तो शुरुआत न करें
- यदि आप धूम्रपान करते हैं, तो इसे छोड़ने की पुरजोर अनुशंसा की जाती है
- स्वास्थ्य सेवा प्रदाता आपको धूम्रपान छोड़ने का सर्वोत्तम तरीका ढूंढने में मदद कर सकते हैं

हृदय रोग की रोकथाम के आवश्यक घटकों के रूप में रक्तचाप नियंत्रण, लिपिड नियंत्रण, मधुमेह प्रबंधन, व्यायाम और सीमित सोडियम सेवन जैसी अन्य हृदय जोखिम प्रबंधन रणनीतियों के साथ धूम्रपान बंद करने का लगातार उल्लेख किया गया है।",10.225383996963501,8.11389684677124,0.038072824478149414,0.5789859294891357,10.187311172485352,7.5349109172821045,claude-sonnet-4-5-20250929,True
हृदय रोग के कौन से जोखिम कारक बदले जा सकते हैं?,hindi,Which risk factors for heart disease can be changed?,". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use

WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use",". The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

SUMMARY: Heart diseaseis the leading cause of the death in the United States. It is also a major cause of disability. But you can take steps to improve your health and help prevent heart disease. The first step is understanding your risk of heart disease. Your risk depends on many factors, some of which are changeable and others that are not. Learning about them and working on the things that you can change can lower your risk of heart disease.What are the heart disease risk factors that I cannot change?There are some risk factors for heart disease that you cannot change:Your age.Your risk of heart disease increases as you get older. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men

. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have.NIH: National Heart, Lung, and Blood Institute","Based on the information provided, the following risk factors for heart disease can be changed:

**Lifestyle habits that can be changed:**

1. **Diet** - A diet high in saturated fats, refined carbohydrates and salt can be changed

2. **Physical Activity** – The habit of not exercising enough can be changed

3. **Alcohol consumption** - The habit of drinking excess alcohol can be controlled

4. **Smoking** – Smoking and exposure to secondhand smoke can be prevented

5. **Stress** – Excessive stress can be managed

The reference clearly mentions that unhealthy lifestyle habits can increase the risk of heart disease over time, and the risk can be reduced by changing these habits.","Based on the provided information, the following risk factors for heart disease **can be changed**:

**Lifestyle habits:**
- **Diet** - Eating a diet high in saturated fats, refined carbohydrates, and salt
- **Physical activity** - Not getting enough physical activity
- **Alcohol consumption** - Drinking too much alcohol
- **Smoking** - Smoking and exposure to secondhand smoke
- **Stress** - Too much stress

**Other medical conditions** - Managing other medical conditions that raise your risk of heart disease (such as high blood pressure, high cholesterol, diabetes)

The context emphasizes that you can lower your risk of heart disease by making heart-healthy lifestyle changes and managing any other medical conditions you have. These modifiable risk factors are important because, unlike age, sex, family history/genetics, and race/ethnicity (which cannot be changed), you have control over these factors and can take action to reduce your risk.",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors ma
---
WARNINGS AND CAUTIONS: 5 WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors ma",". The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
SUMMARY: Heart diseaseis the leading cause of the death in the United States. It is also a major cause of disability. But you can take steps to improve your health and help prevent heart disease. The 
---
. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain hear",Healthcare assistant prompt,"प्रदान की गई जानकारी के आधार पर, हृदय रोग के निम्नलिखित जोखिम कारकों को बदला जा सकता है:

**जीवनशैली की आदतें जिन्हें बदला जा सकता है:**

1. **आहार** - संतृप्त वसा (saturated fats), परिष्कृत कार्बोहाइड्रेट और नमक में उच्च आहार को बदला जा सकता है

2. **शारीरिक गतिविधि** - पर्याप्त व्यायाम न करने की आदत को बदला जा सकता है

3. **शराब का सेवन** - अधिक शराब पीने की आदत को नियंत्रित किया जा सकता है

4. **धूम्रपान** - धूम्रपान और अप्रत्यक्ष धूम्रपान (secondhand smoke) के संपर्क को रोका जा सकता है

5. **तनाव** - अत्यधिक तनाव को प्रबंधित किया जा सकता है

संदर्भ में यह स्पष्ट रूप से उल्लेख किया गया है कि समय के साथ अस्वास्थ्यकर जीवनशैली की आदतें हृदय रोग के जोखिम को बढ़ा सकती हैं, और इन आदतों को बदलकर जोखिम को कम किया जा सकता है।","प्रदान की गई जानकारी के आधार पर, हृदय रोग के लिए निम्नलिखित जोखिम कारकों को **बदला जा सकता है**:

**जीवनशैली की आदतें:**
- **आहार** - संतृप्त वसा, परिष्कृत कार्बोहाइड्रेट और नमक से भरपूर आहार लेना
- **शारीरिक गतिविधि** - पर्याप्त शारीरिक गतिविधि न करना
- **शराब का सेवन** - बहुत अधिक शराब पीना
- **धूम्रपान** - धूम्रपान और निष्क्रिय धूम्रपान के संपर्क में आना
- **तनाव** - बहुत अधिक तनाव

**अन्य चिकित्सीय स्थितियाँ** - अन्य चिकित्सीय स्थितियाँ जो हृदय रोग के खतरे को बढ़ाती हैं (जैसे उच्च रक्तचाप, उच्च कोलेस्ट्रॉल, मधुमेह) का प्रबंधन करना

संदर्भ इस बात पर जोर देता है कि आप हृदय-स्वस्थ जीवनशैली में बदलाव करके और अपनी किसी भी अन्य चिकित्सीय स्थिति का प्रबंधन करके हृदय रोग के जोखिम को कम कर सकते हैं। ये परिवर्तनीय जोखिम कारक महत्वपूर्ण हैं क्योंकि, उम्र, लिंग, पारिवारिक इतिहास/आनुवांशिकी, और नस्ल/जातीयता (जिन्हें बदला नहीं जा सकता) के विपरीत, इन कारकों पर आपका नियंत्रण होता है और आप अपने जोखिम को कम करने के लिए कार्रवाई कर सकते हैं।",9.94139575958252,8.132235527038574,0.039955854415893555,0.453493595123291,9.901439905166626,7.678741931915283,claude-sonnet-4-5-20250929,True
विभिन्न जातीय समूहों में हृदय रोग की दरों में क्या अंतर हैं?,hindi,What are the differences in heart disease rates among different ethnic groups?,". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated to females and other segments of the hypercholesterolemic population. (See also PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility .) Two controlled clinical trials have examined the effects of cholestyramine monotherapy upon coronary atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention Trial 2 , 116 patients (80% male) with coronary artery disease (CAD) documented by arteriography were randomized to cholestyramine resin or placebo for five years of treatment. Final study arteriography revealed progression of coronary artery disease in 49% of placebo patients compared to 32% of the cholestyramine resin group (p<0.05). In the St

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

. Race Pharmacokinetic differences due to race have not been identified. Clinical studies included patients of many races, all of whom responded in a similar fashion. Hepatic Insufficiency Etodolac is predominantly metabolized by the liver. In patients with compensated hepatic cirrhosis, the disposition of total and free etodolac is not altered. Patients with acute and chronic hepatic diseases do not generally require reduced doses of etodolac compared to patients with normal hepatic function. However, etodolac clearance is dependent on liver function and could be reduced in patients with severe hepatic failure. Etodolac plasma protein binding did not change in patients with compensated hepatic cirrhosis given etodolac. Renal Insufficiency Etodolac pharmacokinetics have been investigated in subjects with renal insufficiency. Etodolac renal clearance was unchanged in the presence of mild-to-moderate renal failure (creatinine clearance 37 to 88 mL/min)",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cause of death in the United States, but there are ways to prevent and manage many types of heart disease. There are many different types of heart disease. Some you may be born with, calledcongenital heart disease. Other types develop during your lifetime. Coronary artery disease(also called coronary heart disease) is the most common type of heart disease. It happens slowly over time when a sticky substance called plaque builds up in the arteries that supply your heart muscle with blood. The plaque narrows or blocks blood flow to the heart muscle and can lead to other heart problems: Other types of heart diseases may affect yourheart valvesor heart muscle (cardiomyopathy). The causes of heart disease depend on the type of disease

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others","There are significant differences in rates of heart disease among different ethnic groups:

**Key differences:**

1. **African Americans:** Are more likely to die from heart disease than whites

2. **Hispanic Americans:** Less likely to die from heart disease than whites

3. **Asian Americans:** 
   - Rates of heart disease are lower overall than other groups
   But South Asian Americans have higher rates of heart disease.

4. **High Risk Groups:** 
   - Black people
   - White people
   - American Indian/Alaska Native people

**Important:** Heart disease is the leading cause of death in most racial and ethnic groups in the United States, but the risk is higher in some groups than others.","Based on the provided context, there are notable differences in heart disease rates among different ethnic groups:

**Higher Risk Groups:**
- **African Americans** are more likely than Whites to die of heart disease
- **South Asian Americans** have higher rates of heart disease compared to other Asian American subgroups
- **Black people, White people, and American Indian/Alaska Native people** have particularly high risks and heart disease is the leading cause of death in these groups

**Lower Risk Groups:**
- **Hispanic Americans** are less likely to die of heart disease compared to other groups
- **Asian Americans as a group** have lower rates of heart disease than other groups (though South Asian Americans are an exception with higher rates)

**Important Context:**
Heart disease is the leading cause of death in most racial and ethnic groups in the United States, but the rates and risks vary significantly among different populations. These differences may be influenced by a combination of genetic factors, lifestyle habits, access to healthcare, and other social determinants of health.

It's worth noting that within broader ethnic categories, there can be significant variation in risk, as illustrated by the difference between Asian Americans generally and South Asian Americans specifically.",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
. Race Pharmacokinetic differences due to race have not been identified. Clinical studies included patients of many races, all of whom responded in a similar fashion. Hepatic Insufficiency Etodolac is",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cau
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women",Healthcare assistant prompt,"विभिन्न जातीय समूहों में हृदय रोग की दरों में महत्वपूर्ण अंतर हैं:

**मुख्य अंतर:**

1. **अफ्रीकी अमेरिकी (African Americans):** गोरों की तुलना में हृदय रोग से मृत्यु की संभावना अधिक होती है

2. **हिस्पैनिक अमेरिकी (Hispanic Americans):** गोरों की तुलना में हृदय रोग से मृत्यु की संभावना कम होती है

3. **एशियाई अमेरिकी (Asian Americans):** 
   - समग्र रूप से अन्य समूहों की तुलना में हृदय रोग की दरें कम हैं
   - लेकिन दक्षिण एशियाई अमेरिकियों (South Asian Americans) में हृदय रोग की दरें अधिक हैं

4. **उच्च जोखिम वाले समूह:** 
   - काले लोग (Black people)
   - गोरे लोग (White people)
   - अमेरिकी भारतीय/अलास्का मूल निवासी (American Indian/Alaska Native people)

**महत्वपूर्ण बात:** हृदय रोग संयुक्त राज्य अमेरिका में अधिकांश नस्लीय और जातीय समूहों में मृत्यु का प्रमुख कारण है, लेकिन कुछ समूहों में जोखिम दूसरों की तुलना में अधिक है।","दिए गए संदर्भ के आधार पर, विभिन्न जातीय समूहों के बीच हृदय रोग दर में उल्लेखनीय अंतर हैं:

**उच्च जोखिम समूह:**
- **अफ्रीकी अमेरिकियों** के हृदय रोग से मरने की संभावना श्वेतों की तुलना में अधिक है
- **दक्षिण एशियाई अमेरिकियों** में अन्य एशियाई अमेरिकी उपसमूहों की तुलना में हृदय रोग की दर अधिक है
- **काले लोग, श्वेत लोग, और अमेरिकी भारतीय/अलास्का मूल निवासी** में विशेष रूप से उच्च जोखिम है और हृदय रोग इन समूहों में मृत्यु का प्रमुख कारण है

**कम जोखिम वाले समूह:**
- **हिस्पैनिक अमेरिकियों** में अन्य समूहों की तुलना में हृदय रोग से मरने की संभावना कम है
- **एक समूह के रूप में एशियाई अमेरिकियों** में अन्य समूहों की तुलना में हृदय रोग की दर कम है (हालांकि दक्षिण एशियाई अमेरिकी उच्च दर के साथ एक अपवाद हैं)

**महत्वपूर्ण संदर्भ:**
संयुक्त राज्य अमेरिका में अधिकांश नस्लीय और जातीय समूहों में हृदय रोग मृत्यु का प्रमुख कारण है, लेकिन विभिन्न आबादी के बीच दर और जोखिम काफी भिन्न होते हैं। ये अंतर आनुवंशिक कारकों, जीवनशैली की आदतों, स्वास्थ्य देखभाल तक पहुंच और स्वास्थ्य के अन्य सामाजिक निर्धारकों के संयोजन से प्रभावित हो सकते हैं।

यह ध्यान देने योग्य है कि व्यापक जातीय श्रेणियों के भीतर, जोखिम में महत्वपूर्ण भिन्नता हो सकती है, जैसा कि आम तौर पर एशियाई अमेरिकियों और विशेष रूप से दक्षिण एशियाई अमेरिकियों के बीच अंतर से पता चलता है।",9.84473204612732,9.622453451156616,0.03847980499267578,0.5749309062957764,9.806252241134644,9.04752254486084,claude-sonnet-4-5-20250929,True
शराब के सेवन का हृदय रोग के जोखिम पर क्या प्रभाव पड़ता है?,hindi,What effect does alcohol consumption have on heart disease risk?,". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","The information provided does not contain specific information about the direct effect of alcohol consumption on heart disease risk. 

The information given is only about varenicline (a quit smoking medicine), which states that:

1. **Interaction with Alcohol**: The effects of alcohol may be increased in patients taking Varenicline. Patients are advised to reduce the amount of alcohol consumed.

2. **Cardiovascular events**: Patients who already have heart disease may have an increased risk of cardiovascular events. Patients should inform their doctor about new or worsening heart symptoms.

However, this information is not about the connection between alcohol and heart disease in general. Answering this specific question would require more extensive medical information.","Based on the provided medical context, there is no information about the effect of alcohol consumption on heart disease risk. 

The context only discusses varenicline (a smoking cessation medication) and mentions that:
1. Alcohol has increased effects when combined with varenicline
2. Patients with underlying cardiovascular disease taking varenicline may be at increased risk of cardiovascular events

However, the context does not address the general relationship between alcohol consumption and heart disease risk. To answer your question accurately, I would need additional medical information specifically about alcohol's effects on cardiovascular health.",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"प्रदान की गई जानकारी में शराब के सेवन का हृदय रोग के जोखिम पर सीधे प्रभाव के बारे में विशिष्ट जानकारी नहीं है। 

दी गई जानकारी केवल varenicline (एक धूम्रपान छोड़ने की दवा) के बारे में है, जो बताती है कि:

1. **शराब के साथ परस्पर क्रिया**: Varenicline लेने वाले मरीजों में शराब के प्रभाव बढ़ सकते हैं। मरीजों को शराब की मात्रा कम करने की सलाह दी जाती है।

2. **हृदय संबंधी घटनाएं**: जिन मरीजों को पहले से हृदय रोग है, उनमें हृदय संबंधी घटनाओं का खतरा बढ़ सकता है। मरीजों को नए या बिगड़ते हृदय लक्षणों के बारे में अपने डॉक्टर को सूचित करना चाहिए।

हालांकि, यह जानकारी सामान्य रूप से शराब और हृदय रोग के बीच संबंध के बारे में नहीं है। इस विशिष्ट प्रश्न का उत्तर देने के लिए अधिक व्यापक चिकित्सा जानकारी की आवश्यकता होगी।","दिए गए चिकित्सीय संदर्भ के आधार पर, हृदय रोग के जोखिम पर शराब के सेवन के प्रभाव के बारे में कोई जानकारी नहीं है। 

संदर्भ में केवल वैरेनिकलाइन (धूम्रपान बंद करने की दवा) पर चर्चा की गई है और उल्लेख किया गया है कि:
1. वैरेनिकलाइन के साथ मिलाने पर अल्कोहल का प्रभाव बढ़ जाता है
2. अंतर्निहित हृदय रोग वाले मरीजों में वैरेनिकलाइन लेने से हृदय संबंधी घटनाओं का खतरा बढ़ सकता है

हालाँकि, संदर्भ शराब के सेवन और हृदय रोग के जोखिम के बीच सामान्य संबंध को संबोधित नहीं करता है। आपके प्रश्न का सटीक उत्तर देने के लिए, मुझे विशेष रूप से हृदय स्वास्थ्य पर शराब के प्रभाव के बारे में अतिरिक्त चिकित्सा जानकारी की आवश्यकता होगी।",9.555461168289185,6.180486679077148,0.03501749038696289,0.5094470977783203,9.520443677902222,5.671039581298828,claude-sonnet-4-5-20250929,True
अतिरिक्त कैलोरी का हृदय रोग के जोखिम पर क्या प्रभाव पड़ता है?,hindi,What effect does excess calories have on heart disease risk?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan lower these risks.Eating a healthy diet.Try to limit saturatedfats, foods high insodium(salt), and addedsugars. Instead, eat plenty of fresh fruit, vegetables, and whole grains. TheDASH dietis an example of an eating plan that can help you to lower your blood pressure and cholesterol, two things that can lower your risk of heart disease.Getting regular physical activity.Regular physical activity has many benefits, including strengthening your heart and improving your circulation. It can also help you maintain a healthy weight and lower cholesterol and blood pressure. All of these can lower your risk of heart disease.Limitingalcohol.Drinking too much alcohol can raise your blood pressure. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease

WARNINGS: WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups ( Diabetes , 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan lower these risks.Eating a healthy diet.Try to limit saturatedfats, foods high insodium(salt), and addedsugars. Instead, eat plenty of fresh fruit, vegetables, and whole grains. TheDASH dietis an example of an eating plan that can help you to lower your blood pressure and cholesterol, two things that can lower your risk of heart disease.Getting regular physical activity.Regular physical activity has many benefits, including strengthening your heart and improving your circulation. It can also help you maintain a healthy weight and lower cholesterol and blood pressure. All of these can lower your risk of heart disease.Limitingalcohol.Drinking too much alcohol can raise your blood pressure. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease

. Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of anti-diabetic medications. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. Early warning symptoms of hypoglycemia may be different or less pronounced in patients with autonomic neuropathy, the elderly, and in patients who are taking beta-adrenergic blocking medications or other sympatholytic agents. These situations may result in severe hypoglycemia before the patient is aware of the hypoglycemia. These impairments may present a risk in situations where these abilities are especially important, such as driving or operating other machinery

. Fluid and Electrolyte Disturbances congestive heart failure in susceptible patients, fluid retention, hypokalemia, hypokalemic alkalosis, metabolic alkalosis, hypotension or shock-like reaction, potassium loss, sodium retention with resulting edema. Gastrointestinal abdominal distention, abdominal pain, anorexia which may result in weight loss, constipation, diarrhea, elevation in serum liver enzyme levels (usually reversible upon discontinuation), gastric irritation, hepatomegaly, increased appetite and weight gain, nausea, oropharyngeal candidiasis, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis, vomiting. Hematologic anemia, neutropenia (including febrile neutropenia). Metabolic negative nitrogen balance due to protein catabolism

. Fluid and Electrolyte Disturbances congestive heart failure in susceptible patients, fluid retention, hypokalemia, hypokalemic alkalosis, metabolic alkalosis, hypotension or shock-like reaction, potassium loss, sodium retention with resulting edema. Gastrointestinal abdominal distention, abdominal pain, anorexia which may result in weight loss, constipation, diarrhea, elevation in serum liver enzyme levels (usually reversible upon discontinuation), gastric irritation, hepatomegaly, increased appetite and weight gain, nausea, oropharyngeal candidiasis, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis, vomiting. Hematologic anemia, neutropenia (including febrile neutropenia). Metabolic negative nitrogen balance due to protein catabolism","Excess calories have the following effects on heart disease risk:

**Weight Gain**: Excess calories can lead to weight gain, which increases the risk of heart disease.

**Increased blood pressure**: Excess calories, especially calories from alcohol, can increase blood pressure.

**Relation to other risk factors**: Weight gain can lead to the following problems:
- high blood cholesterol
- high triglyceride levels
- high blood pressure
- diabetes

All these factors increase the risk of heart disease.

**Preventive measures**:
- Eat a healthy diet – limit saturated fat, salt and added sugars
- Eat fresh fruits, vegetables and whole grains
- do regular physical activity
- maintain a healthy weight

Thus, excess calories","Based on the provided context, excess calories increase heart disease risk through the following mechanism:

**Excess calories cause weight gain, which raises the risk of heart disease.**

The context specifically states that drinking too much alcohol ""adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease.""

Additionally, the context emphasizes that **controlling your weight can lower heart disease risks** because weight is linked to other heart disease risk factors, including:
- High blood cholesterol
- High triglyceride levels
- High blood pressure
- Diabetes

Therefore, excess calories contribute to heart disease risk primarily by leading to weight gain, which in turn is associated with multiple cardiovascular risk factors.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan low
---
WARNINGS: WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortalit
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan low
---
. Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of anti-diabetic medications. Hypoglycemia is a
---
. Fluid and Electrolyte Disturbances congestive heart failure in susceptible patients, fluid retention, hypokalemia, hypokalemic alkalosis, metabolic alkalosis, hypotension or shock-like reaction, pot
---
. Fluid and Electrolyte Disturbances congestive heart failure in susceptible patients, fluid retention, hypokalemia, hypokalemic alkalosis, metabolic alkalosis, hypotension or shock-like reaction, pot",Healthcare assistant prompt,"अतिरिक्त कैलोरी का हृदय रोग के जोखिम पर निम्नलिखित प्रभाव पड़ता है:

**वजन बढ़ना**: अतिरिक्त कैलोरी से वजन बढ़ सकता है, जो हृदय रोग के जोखिम को बढ़ाता है।

**रक्तचाप में वृद्धि**: अधिक कैलोरी, विशेष रूप से शराब से मिलने वाली कैलोरी, रक्तचाप को बढ़ा सकती है।

**अन्य जोखिम कारकों से संबंध**: वजन बढ़ने से निम्नलिखित समस्याएं हो सकती हैं:
- उच्च रक्त कोलेस्ट्रॉल
- उच्च ट्राइग्लिसराइड स्तर
- उच्च रक्तचाप
- मधुमेह

ये सभी कारक हृदय रोग के जोखिम को बढ़ाते हैं।

**रोकथाम के उपाय**:
- स्वस्थ आहार लें - संतृप्त वसा, नमक और अतिरिक्त शक्कर को सीमित करें
- ताजे फल, सब्जियां और साबुत अनाज खाएं
- नियमित शारीरिक गतिविधि करें
- स्वस्थ वजन बनाए रखें

इस प्रकार, अतिरिक्त कैलोरी का स","दिए गए संदर्भ के आधार पर, अतिरिक्त कैलोरी निम्नलिखित तंत्र के माध्यम से हृदय रोग के खतरे को बढ़ाती है:

**अतिरिक्त कैलोरी से वजन बढ़ता है, जिससे हृदय रोग का खतरा बढ़ जाता है।**

संदर्भ विशेष रूप से बताता है कि बहुत अधिक शराब पीने से ""अतिरिक्त कैलोरी बढ़ती है, जिससे वजन बढ़ सकता है। इन दोनों से हृदय रोग का खतरा बढ़ जाता है।""

इसके अतिरिक्त, संदर्भ इस बात पर जोर देता है कि **अपने वजन को नियंत्रित करने से हृदय रोग के जोखिम कम हो सकते हैं** क्योंकि वजन अन्य हृदय रोग जोखिम कारकों से जुड़ा होता है, जिनमें शामिल हैं:
- उच्च रक्त कोलेस्ट्रॉल
- उच्च ट्राइग्लिसराइड स्तर
- उच्च रक्तचाप
- मधुमेह

इसलिए, अतिरिक्त कैलोरी मुख्य रूप से वजन बढ़ाकर हृदय रोग के जोखिम में योगदान करती है, जो बदले में कई हृदय जोखिम कारकों से जुड़ी होती है।",9.431009531021118,7.1883039474487305,0.02895665168762207,0.5073626041412354,9.402052879333496,6.680941343307495,claude-sonnet-4-5-20250929,True
तनाव का हृदय रोग से क्या संबंध है?,hindi,How is stress related to heart disease?,". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This isatherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). Ablood clotcan form around the plaque and block the artery. A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery. At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and differentheart health tests. Treatments may include medicines and medical procedures such ascoronary angioplasty. After a heart attack,cardiac rehabilitationand lifestyle changes can help you recover. NIH: National Heart, Lung, and Blood Institute

WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn

WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This isatherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). Ablood clotcan form around the plaque and block the artery. A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery. At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and differentheart health tests. Treatments may include medicines and medical procedures such ascoronary angioplasty. After a heart attack,cardiac rehabilitationand lifestyle changes can help you recover. NIH: National Heart, Lung, and Blood Institute

. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy. Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy

. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy. Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have","There is a significant relationship between stress and heart disease:

**Direct effects of stress:**
- Excessive stress can be a ""trigger"" or factor for a heart attack.

**Unhealthy ways to deal with stress:**
Some common ways of dealing with stress are harmful for the heart, such as:
- overeating
- excessive drinking
- to smoke

**Healthy ways to manage stress:**
You can control stress in the following ways:
- to exercise
- listening to music
- focusing on something calm or pleasant
- to meditate

Therefore, managing stress effectively is very important for heart health.","Based on the provided context, stress is related to heart disease in several important ways:

1. **Direct Trigger**: Extreme stress can act as a ""trigger"" for a heart attack, potentially precipitating a cardiac event in susceptible individuals.

2. **Indirect Effects Through Unhealthy Coping Mechanisms**: Common ways people cope with stress can be harmful to heart health, including:
   - Overeating
   - Heavy drinking
   - Smoking

These stress-related behaviors can contribute to heart disease risk over time.

3. **Sleep Disruption**: Stress can interfere with getting enough sleep, which raises the risk of:
   - High blood pressure
   - Obesity
   - Diabetes
   
All three of these conditions increase the risk of heart disease.

**Recommended Stress Management Strategies** to protect heart health include:
- Exercise
- Listening to music
- Focusing on something calm or peaceful
- Meditating

By managing stress through healthy methods rather than harmful coping mechanisms, you can help reduce your risk of heart disease and heart attacks.",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, t
---
WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the poten
---
WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the poten
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, t
---
. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irri
---
. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irri
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make",Healthcare assistant prompt,"तनाव और हृदय रोग के बीच महत्वपूर्ण संबंध है:

**तनाव के प्रत्यक्ष प्रभाव:**
- अत्यधिक तनाव हृदयाघात (heart attack) के लिए एक ""ट्रिगर"" या कारक हो सकता है

**तनाव से निपटने के अस्वास्थ्यकर तरीके:**
तनाव से निपटने के कुछ सामान्य तरीके हृदय के लिए हानिकारक होते हैं, जैसे:
- अधिक खाना
- अत्यधिक शराब पीना
- धूम्रपान करना

**तनाव प्रबंधन के स्वास्थ्यकर तरीके:**
आप निम्नलिखित तरीकों से तनाव को नियंत्रित कर सकते हैं:
- व्यायाम करना
- संगीत सुनना
- किसी शांत या सुखद चीज़ पर ध्यान केंद्रित करना
- ध्यान (meditation) करना

इसलिए, तनाव को प्रभावी ढंग से प्रबंधित करना हृदय स्वास्थ्य के लिए बहुत महत्वपूर्ण है।","दिए गए संदर्भ के आधार पर, तनाव कई महत्वपूर्ण तरीकों से हृदय रोग से संबंधित है:

1. **प्रत्यक्ष ट्रिगर**: अत्यधिक तनाव दिल के दौरे के लिए ""ट्रिगर"" के रूप में कार्य कर सकता है, जो संभावित रूप से अतिसंवेदनशील व्यक्तियों में हृदय संबंधी घटना को जन्म दे सकता है।

2. **अस्वस्थ मुकाबला तंत्र के माध्यम से अप्रत्यक्ष प्रभाव**: लोगों द्वारा तनाव से निपटने के सामान्य तरीके हृदय स्वास्थ्य के लिए हानिकारक हो सकते हैं, जिनमें शामिल हैं:
   - ज़्यादा खाना
   - अत्यधिक शराब पीना
   - धूम्रपान

ये तनाव-संबंधी व्यवहार समय के साथ हृदय रोग के जोखिम में योगदान कर सकते हैं।

3. **नींद में खलल**: तनाव पर्याप्त नींद लेने में बाधा डाल सकता है, जिससे निम्न का खतरा बढ़ जाता है:
   - उच्च रक्तचाप
   - मोटापा
   - मधुमेह
   
इन तीनों स्थितियों से हृदय रोग का खतरा बढ़ जाता है।

**हृदय स्वास्थ्य की रक्षा के लिए अनुशंसित तनाव प्रबंधन रणनीतियाँ** में शामिल हैं:
- व्यायाम
- संगीत सुनना
- शांत या शांत किसी चीज़ पर ध्यान केंद्रित करना
- ध्यान करना

हानिकारक मुकाबला तंत्र के बजाय स्वस्थ तरीकों के माध्यम से तनाव का प्रबंधन करके, आप हृदय रोग और दिल के दौरे के जोखिम को कम करने में मदद कर सकते हैं।",9.380351543426514,9.06050443649292,0.020033597946166992,0.5345809459686279,9.360317945480347,8.525923490524292,claude-sonnet-4-5-20250929,True
कौन सा जातीय समूह अन्य की तुलना में हृदय रोग की दरों में कम है?,hindi,Which ethnic group has lower rates of heart disease than others?,". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated to females and other segments of the hypercholesterolemic population. (See also PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility .) Two controlled clinical trials have examined the effects of cholestyramine monotherapy upon coronary atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention Trial 2 , 116 patients (80% male) with coronary artery disease (CAD) documented by arteriography were randomized to cholestyramine resin or placebo for five years of treatment. Final study arteriography revealed progression of coronary artery disease in 49% of placebo patients compared to 32% of the cholestyramine resin group (p<0.05). In the St

. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris

. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cause of death in the United States, but there are ways to prevent and manage many types of heart disease. There are many different types of heart disease. Some you may be born with, calledcongenital heart disease. Other types develop during your lifetime. Coronary artery disease(also called coronary heart disease) is the most common type of heart disease. It happens slowly over time when a sticky substance called plaque builds up in the arteries that supply your heart muscle with blood. The plaque narrows or blocks blood flow to the heart muscle and can lead to other heart problems: Other types of heart diseases may affect yourheart valvesor heart muscle (cardiomyopathy). The causes of heart disease depend on the type of disease

. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32 percent fewer first hospitalizations for heart failure, and 32 percent fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect

. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32 percent fewer first hospitalizations for heart failure, and 32 percent fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect","According to the information provided, **Hispanic Americans** are less likely to die from heart disease than other groups.

Additionally, **Asian Americans** as a group have lower rates of heart disease than other groups. However, it's worth noting that South Asian Americans have higher rates of heart disease.

The context also states that heart disease is the leading cause of death in most racial and ethnic groups in the United States, but the risk is higher among Black people, White people, and American Indian/Alaska Native people.","Based on the provided context, **Hispanic Americans** and **Asian Americans** as a group have lower rates of heart disease than other groups.

Specifically, the context states:
- Hispanic Americans are less likely to die of heart disease compared to other groups
- Asian Americans as a group have lower rates of heart disease than other groups

However, it's important to note that within the Asian American population, there is variation - South Asian Americans actually have higher rates of heart disease compared to other Asian American subgroups.",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be
---
. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of t
---
. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of t",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cau
---
. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 3
---
. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 3",Healthcare assistant prompt,"प्रदान की गई जानकारी के अनुसार, **हिस्पैनिक अमेरिकी (Hispanic Americans)** अन्य समूहों की तुलना में हृदय रोग से मरने की संभावना कम होती है।

इसके अतिरिक्त, **एशियाई अमेरिकी (Asian Americans)** समूह के रूप में अन्य समूहों की तुलना में हृदय रोग की कम दरें रखते हैं। हालांकि, यह ध्यान देने योग्य है कि दक्षिण एशियाई अमेरिकियों (South Asian Americans) में हृदय रोग की दरें अधिक होती हैं।

संदर्भ में यह भी बताया गया है कि संयुक्त राज्य अमेरिका में अधिकांश नस्लीय और जातीय समूहों में हृदय रोग मृत्यु का प्रमुख कारण है, लेकिन काले लोगों (Black people), सफेद लोगों (White people), और अमेरिकी भारतीय/अलास्का मूल निवासी लोगों (American Indian/Alaska Native people) में जोखिम अधिक है।","दिए गए संदर्भ के आधार पर, एक समूह के रूप में **हिस्पैनिक अमेरिकियों** और **एशियाई अमेरिकियों** में हृदय रोग की दर अन्य समूहों की तुलना में कम है।

विशेष रूप से, संदर्भ बताता है:
- हिस्पैनिक अमेरिकियों में अन्य समूहों की तुलना में हृदय रोग से मरने की संभावना कम है
- एक समूह के रूप में एशियाई अमेरिकियों में अन्य समूहों की तुलना में हृदय रोग की दर कम है

हालाँकि, यह ध्यान रखना महत्वपूर्ण है कि एशियाई अमेरिकी आबादी के भीतर भिन्नता है - दक्षिण एशियाई अमेरिकियों में वास्तव में अन्य एशियाई अमेरिकी उपसमूहों की तुलना में हृदय रोग की दर अधिक है।",9.348140001296997,6.1111719608306885,0.027837038040161133,0.5409877300262451,9.320302963256836,5.570184230804443,claude-sonnet-4-5-20250929,True
परिवार के सदस्यों के लिए हृदय रोग निदान की आयु सीमाएं क्या हैं जो जोखिम बढ़ाती हैं?,hindi,What are the age ranges for heart disease diagnosis for family members that increase risk?,". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them",". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others","According to the information provided, the age ranges for early diagnosis of heart disease in family members that increase your risk are as follows:

**For male family members:**
- If your father or brother was diagnosed with heart disease **before the age of 55**

**For female family members:**
- If your mother or sister was diagnosed with heart disease **before the age of 65**

If your close family members have had heart disease before these age ranges, you are at higher risk for heart disease. This family history is an important risk factor that should be taken into account.","Based on the provided context, a family history of heart disease increases your risk if you have a close family member who was diagnosed at an early age, specifically:

- **Father or brother**: diagnosed before age 55
- **Mother or sister**: diagnosed before age 65

Having a family member diagnosed with heart disease at these younger ages indicates a greater risk for developing heart disease yourself.",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t",". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women",Healthcare assistant prompt,"प्रदान की गई जानकारी के अनुसार, परिवार के सदस्यों में हृदय रोग के शुरुआती निदान की आयु सीमाएं जो आपके जोखिम को बढ़ाती हैं, निम्नलिखित हैं:

**पुरुष परिवार के सदस्यों के लिए:**
- यदि आपके पिता या भाई को **55 वर्ष की आयु से पहले** हृदय रोग का निदान हुआ था

**महिला परिवार के सदस्यों के लिए:**
- यदि आपकी माता या बहन को **65 वर्ष की आयु से पहले** हृदय रोग का निदान हुआ था

यदि आपके करीबी परिवार के सदस्यों को इन आयु सीमाओं से पहले हृदय रोग हुआ है, तो आपको हृदय रोग का अधिक जोखिम होता है। यह पारिवारिक इतिहास एक महत्वपूर्ण जोखिम कारक है जिसे ध्यान में रखना चाहिए।","दिए गए संदर्भ के आधार पर, हृदय रोग का पारिवारिक इतिहास आपके जोखिम को बढ़ाता है यदि आपके परिवार का कोई करीबी सदस्य है जिसका निदान कम उम्र में किया गया था, विशेष रूप से:

- **पिता या भाई**: 55 वर्ष की आयु से पहले निदान किया गया
- **माँ या बहन**: 65 वर्ष की आयु से पहले निदान किया गया

इतनी कम उम्र में परिवार के किसी सदस्य को हृदय रोग का पता चलना स्वयं हृदय रोग विकसित होने के अधिक जोखिम का संकेत देता है।",7.911682367324829,6.463819265365601,0.0497286319732666,0.5112631320953369,7.8619537353515625,5.952556133270264,claude-sonnet-4-5-20250929,True
अनुशंसित शराब से अधिक पीने के हृदय रोग जोखिम पर क्या प्रभाव होते हैं?,hindi,What are the effects of drinking more alcohol than recommended on heart disease risk?,". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","The information provided does not provide specific details about the direct effects on heart disease risk of drinking more than the recommended amount of alcohol.

However, the following important points regarding the drug varenicline are mentioned in the given information:

1. **Interaction with Alcohol**: Enhanced effects of alcohol have been observed in patients taking varenicline. Patients are advised to limit the amount of alcohol they consume until they know how varenicline affects them.

2. **Cardiovascular events**: Patients who already have heart disease may have an increased risk of cardiovascular events. Patients should notify their healthcare provider of new or worsening heart symptoms.

If you would like detailed information about alcohol consumption and heart disease, please consult with your doctor at","Based on the provided medical information, drinking more alcohol than recommended increases your risk of heart disease in two main ways:

1. **Raises blood pressure** - Excessive alcohol consumption elevates blood pressure, which is a significant risk factor for heart disease.

2. **Causes weight gain** - Alcohol adds extra calories that can lead to weight gain, which also increases heart disease risk.

The recommended limits to minimize these risks are:
- **Men**: No more than 2 drinks per day
- **Women**: No more than 1 drink per day

The context also notes that heavy drinking is considered a harmful way of coping with stress and is bad for your heart. Additionally, when combined with certain medications like varenicline (a smoking cessation drug), alcohol can have increased effects, making it important to reduce consumption.

The best option for heart health is not to drink alcohol at all, but if you do choose to drink, staying within these recommended limits is important for reducing your cardiovascular disease risk.",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"प्रदान की गई जानकारी में अनुशंसित मात्रा से अधिक शराब पीने के हृदय रोग जोखिम पर सीधे प्रभावों के बारे में विशिष्ट विवरण नहीं दिया गया है।

हालांकि, दी गई जानकारी में varenicline दवा के संदर्भ में निम्नलिखित महत्वपूर्ण बिंदु बताए गए हैं:

1. **शराब के साथ परस्पर क्रिया**: Varenicline लेने वाले मरीजों में शराब के बढ़े हुए प्रभाव देखे गए हैं। मरीजों को सलाह दी जाती है कि वे शराब की मात्रा कम करें जब तक उन्हें यह पता न चल जाए कि varenicline उन्हें कैसे प्रभावित करता है।

2. **हृदय संबंधी घटनाएं**: जिन मरीजों को पहले से हृदय रोग है, उनमें हृदय संबंधी घटनाओं का जोखिम बढ़ सकता है। मरीजों को नए या बिगड़ते हृदय लक्षणों के बारे में अपने स्वास्थ्य सेवा प्रदाता को सूचित करना चाहिए।

यदि आप शराब के सेवन और हृदय रोग के बारे में विस्तृत जानकारी चाहते हैं, तो कृपया अपने डॉक्टर से पर","प्रदान की गई चिकित्सा जानकारी के आधार पर, अनुशंसित से अधिक शराब पीने से हृदय रोग का खतरा दो मुख्य तरीकों से बढ़ जाता है:

1. **रक्तचाप बढ़ाता है** - अत्यधिक शराब का सेवन रक्तचाप बढ़ाता है, जो हृदय रोग के लिए एक महत्वपूर्ण जोखिम कारक है।

2. **वजन बढ़ने का कारण** - शराब अतिरिक्त कैलोरी जोड़ती है जिससे वजन बढ़ सकता है, जिससे हृदय रोग का खतरा भी बढ़ जाता है।

इन जोखिमों को कम करने के लिए अनुशंसित सीमाएँ हैं:
- **पुरुष**: प्रति दिन 2 से अधिक पेय नहीं
- **महिलाएं**: प्रति दिन 1 से अधिक पेय नहीं

संदर्भ में यह भी कहा गया है कि भारी शराब पीना तनाव से निपटने का एक हानिकारक तरीका माना जाता है और यह आपके दिल के लिए बुरा है। इसके अतिरिक्त, जब वैरेनिकलाइन (धूम्रपान बंद करने वाली दवा) जैसी कुछ दवाओं के साथ मिलाया जाता है, तो शराब का प्रभाव बढ़ सकता है, जिससे इसका सेवन कम करना महत्वपूर्ण हो जाता है।

हृदय स्वास्थ्य के लिए सबसे अच्छा विकल्प बिल्कुल भी शराब नहीं पीना है, लेकिन यदि आप शराब पीना चुनते हैं, तो इन अनुशंसित सीमाओं के भीतर रहना आपके हृदय रोग के जोखिम को कम करने के लिए महत्वपूर्ण है।",9.890634059906006,8.56269097328186,0.02850031852722168,0.6326143741607666,9.862133741378784,7.930076599121094,claude-sonnet-4-5-20250929,True
पुरुषों और महिलाओं के लिए हृदय रोग के जोखिम को कम करने के लिए पीने के दिशा-निर्देश क्या हैं?,hindi,What are the drinking guidelines for men and women to reduce heart disease risk?,". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)","According to the information provided, the following are guidelines for drinking (alcohol) to reduce the risk of heart disease:

**For Men:**
- Should not have more than 2 drinks per day

**For Women:**
- Should not have more than 1 drink per day

**Important advice:**
- It's best not to drink alcohol
Drinking alcohol provides extra calories, which can lead to weight gain.
- Both conditions increase the risk of heart disease

If you drink alcohol, following these limits is important for heart health.","Based on the provided context, the drinking guidelines to reduce heart disease risk are:

**For Men:** No more than 2 drinks per day

**For Women:** No more than 1 drink per day

The context notes that while it's best not to drink alcohol at all, these are the recommended limits if you do choose to drink. Alcohol can raise blood pressure and add extra calories that may cause weight gain, both of which increase the risk of heart disease.",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten",Healthcare assistant prompt,"प्रदान की गई जानकारी के अनुसार, हृदय रोग के जोखिम को कम करने के लिए पीने (शराब) के दिशा-निर्देश निम्नलिखित हैं:

**पुरुषों के लिए:**
- प्रति दिन 2 से अधिक ड्रिंक नहीं लेनी चाहिए

**महिलाओं के लिए:**
- प्रति दिन 1 से अधिक ड्रिंक नहीं लेनी चाहिए

**महत्वपूर्ण सलाह:**
- सबसे अच्छा यह है कि शराब न पिएं
- शराब पीने से अतिरिक्त कैलोरी मिलती है, जिससे वजन बढ़ सकता है
- दोनों ही स्थितियां हृदय रोग के जोखिम को बढ़ाती हैं

यदि आप शराब पीते हैं, तो इन सीमाओं का पालन करना हृदय स्वास्थ्य के लिए महत्वपूर्ण है।","दिए गए संदर्भ के आधार पर, हृदय रोग के जोखिम को कम करने के लिए शराब पीने के दिशानिर्देश हैं:

**पुरुषों के लिए:** प्रति दिन 2 से अधिक पेय नहीं

**महिलाओं के लिए:** प्रति दिन 1 से अधिक पेय नहीं

संदर्भ में कहा गया है कि हालांकि शराब बिल्कुल न पीना ही सबसे अच्छा है, लेकिन यदि आप शराब पीना चुनते हैं तो ये अनुशंसित सीमाएँ हैं। शराब रक्तचाप बढ़ा सकती है और अतिरिक्त कैलोरी बढ़ा सकती है जिससे वजन बढ़ सकता है, इन दोनों से हृदय रोग का खतरा बढ़ जाता है।",7.856238126754761,6.019787311553955,0.04763340950012207,0.5803916454315186,7.808604717254639,5.4393956661224365,claude-sonnet-4-5-20250929,True
तनाव प्रबंधन हृदय रोग के जोखिम को कैसे प्रभावित करता है?,hindi,How does stress management affect heart disease risk?,". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn","According to the information provided, stress management affects heart disease risk in the following ways:

**Effect of stress:**
- Excessive stress can be a ""trigger"" for a heart attack.
- Common ways of dealing with stress such as overeating, excessive drinking and smoking are harmful for the heart

**Beneficial ways to manage stress:**
1. **Exercise** – Regular physical activity
2. **Listening to Music** – Helps calm the mind
3. **Focusing on calm or pleasant things**
4. **Meditation** - For mental peace

**Other associated risk factors:**
Apart from stress, the following things also increase the risk of heart disease:
- not getting enough sleep
- Diabetes
- high blood pressure
- obesity

Therefore, proper stress management techniques should be adopted.","Based on the provided context, stress management plays an important role in reducing heart disease risk in several ways:

1. **Direct Impact**: Extreme stress can act as a ""trigger"" for a heart attack.

2. **Indirect Impact Through Unhealthy Coping Behaviors**: Common ways people cope with stress—such as overeating, heavy drinking, and smoking—are harmful to heart health and can increase heart disease risk.

3. **Effective Stress Management Strategies**: The context identifies several beneficial ways to manage stress that can help protect heart health:
   - Exercise
   - Listening to music
   - Focusing on something calm or peaceful
   - Meditating

By managing stress effectively through these healthier methods rather than through harmful coping mechanisms, individuals can reduce their risk of heart disease. The context suggests that stress management is part of a comprehensive approach to heart health, alongside other factors like managing diabetes and getting adequate sleep.",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres",Healthcare assistant prompt,"प्रदान की गई जानकारी के अनुसार, तनाव प्रबंधन हृदय रोग के जोखिम को निम्नलिखित तरीकों से प्रभावित करता है:

**तनाव का प्रभाव:**
- अत्यधिक तनाव हृदय आघात (heart attack) के लिए एक ""ट्रिगर"" हो सकता है
- तनाव से निपटने के सामान्य तरीके जैसे अधिक खाना, अत्यधिक शराब पीना और धूम्रपान करना हृदय के लिए हानिकारक हैं

**तनाव प्रबंधन के लाभकारी तरीके:**
1. **व्यायाम** - नियमित शारीरिक गतिविधि
2. **संगीत सुनना** - मन को शांत करने में मदद करता है
3. **शांत या सुखद चीजों पर ध्यान केंद्रित करना**
4. **ध्यान (मेडिटेशन)** - मानसिक शांति के लिए

**अन्य संबंधित जोखिम कारक:**
तनाव के अलावा, निम्नलिखित चीजें भी हृदय रोग के जोखिम को बढ़ाती हैं:
- पर्याप्त नींद न लेना
- मधुमेह (डायबिटीज)
- उच्च रक्तचाप
- मोटापा

इसलिए, उचित तनाव प्रबंधन तकनीकों को अ","दिए गए संदर्भ के आधार पर, तनाव प्रबंधन कई मायनों में हृदय रोग के जोखिम को कम करने में महत्वपूर्ण भूमिका निभाता है:

1. **प्रत्यक्ष प्रभाव**: अत्यधिक तनाव दिल के दौरे के लिए ""ट्रिगर"" के रूप में कार्य कर सकता है।

2. **अस्वस्थ व्यवहार के माध्यम से अप्रत्यक्ष प्रभाव**: लोगों द्वारा तनाव से निपटने के सामान्य तरीके - जैसे अधिक खाना, भारी शराब पीना और धूम्रपान - हृदय स्वास्थ्य के लिए हानिकारक हैं और हृदय रोग का खतरा बढ़ सकता है।

3. **प्रभावी तनाव प्रबंधन रणनीतियाँ**: संदर्भ तनाव को प्रबंधित करने के कई लाभकारी तरीकों की पहचान करता है जो हृदय स्वास्थ्य की रक्षा में मदद कर सकते हैं:
   - व्यायाम
   - संगीत सुनना
   - शांत या शांत किसी चीज़ पर ध्यान केंद्रित करना
   - ध्यान करना

हानिकारक मुकाबला तंत्रों के बजाय इन स्वस्थ तरीकों के माध्यम से तनाव को प्रभावी ढंग से प्रबंधित करके, व्यक्ति हृदय रोग के जोखिम को कम कर सकते हैं। संदर्भ से पता चलता है कि मधुमेह के प्रबंधन और पर्याप्त नींद लेने जैसे अन्य कारकों के साथ-साथ तनाव प्रबंधन हृदय स्वास्थ्य के लिए एक व्यापक दृष्टिकोण का हिस्सा है।",70.26097679138184,7.764100074768066,0.033980369567871094,0.4405808448791504,70.22699642181396,7.323519229888916,claude-sonnet-4-5-20250929,True
धूम्रपान करने वालों के लिए हृदय रोग के जोखिम को कम करने के लिए क्या अनुशंसित कार्रवाई है?,hindi,What is the recommended action for smokers to reduce the risk of heart disease?,". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Advise patients to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how varenicline may affect them. 5.5 Cardiovascular Events A comprehensive evaluation of cardiovascular (CV) risk with varenicline suggests that patients with underlying CV disease may be at increased risk; however, these concerns must be balanced with the health benefits of smoking cessation. CV risk has been assessed for varenicline in randomized controlled trials (RCT) and meta-analyses of RCTs. In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with varenicline compared to placebo. All-cause and CV mortality was lower in patients treated with varenicline [see Clinical Studies (14.8) ]

. Advise patients to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how varenicline may affect them. 5.5 Cardiovascular Events A comprehensive evaluation of cardiovascular (CV) risk with varenicline suggests that patients with underlying CV disease may be at increased risk; however, these concerns must be balanced with the health benefits of smoking cessation. CV risk has been assessed for varenicline in randomized controlled trials (RCT) and meta-analyses of RCTs. In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with varenicline compared to placebo. All-cause and CV mortality was lower in patients treated with varenicline [see Clinical Studies (14.8) ]",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have.NIH: National Heart, Lung, and Blood Institute

. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have. Possible treatments may include: You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have. NIH: National Heart, Lung, and Blood Institute","The following actions are recommended for smokers to reduce their risk of heart disease:

**Main action:**
1. **Quit Smoking** – This is the most important step

**Comprehensive cardiovascular risk management should include:**

2. **Blood pressure control** – Controlling high blood pressure is essential, as lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events (especially stroke and myocardial infarction)

3. **Lipid Control** – Management of Cholesterol

4. **Diabetes Management** - If there is diabetes then its proper control.

5. **Antithrombotic Therapy** - as appropriate

6. **Exercise** – Regular physical activity

7. **Limited sodium intake** – Less use of salt

As per the information provided","Based on the provided context, the recommended action for smokers to reduce the risk of heart disease is **smoking cessation** (quitting smoking).

The context specifically mentions smoking cessation as part of comprehensive cardiovascular risk management. It states that ""Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, **smoking cessation**, exercise, and limited sodium intake.""

Additionally, the context identifies smoking as a risk factor for coronary heart disease in multiple instances, and indicates that making heart-healthy lifestyle changes can help lower the risk of heart diseases. Smoking cessation is a key component of these heart-healthy lifestyle modifications.",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Advise patients to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how varenicline may affect them. 5.5 Cardiovascular Events A compr
---
. Advise patients to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how varenicline may affect them. 5.5 Cardiovascular Events A compr",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain hear
---
. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have. Possible treatments may include: You may be ",Healthcare assistant prompt,"धूम्रपान करने वालों के लिए हृदय रोग के जोखिम को कम करने के लिए निम्नलिखित कार्रवाइयां अनुशंसित हैं:

**मुख्य कार्रवाई:**
1. **धूम्रपान बंद करना** - यह सबसे महत्वपूर्ण कदम है

**व्यापक हृदय जोखिम प्रबंधन में शामिल होना चाहिए:**

2. **रक्तचाप नियंत्रण** - उच्च रक्तचाप को नियंत्रित करना आवश्यक है, क्योंकि रक्तचाप कम करने से घातक और गैर-घातक हृदय संबंधी घटनाओं (विशेष रूप से स्ट्रोक और मायोकार्डियल इन्फार्क्शन) का जोखिम कम होता है

3. **लिपिड नियंत्रण** - कोलेस्ट्रॉल का प्रबंधन

4. **मधुमेह प्रबंधन** - यदि मधुमेह है तो उसका उचित नियंत्रण

5. **एंटीथ्रोम्बोटिक थेरेपी** - जैसा उपयुक्त हो

6. **व्यायाम** - नियमित शारीरिक गतिविधि

7. **सोडियम का सीमित सेवन** - नमक का कम उपयोग

प्रदान की गई जानकारी के अनुसार","दिए गए संदर्भ के आधार पर, हृदय रोग के जोखिम को कम करने के लिए धूम्रपान करने वालों के लिए अनुशंसित कार्रवाई **धूम्रपान बंद करना** (धूम्रपान छोड़ना) है।

संदर्भ में विशेष रूप से व्यापक हृदय जोखिम प्रबंधन के हिस्से के रूप में धूम्रपान बंद करने का उल्लेख किया गया है। इसमें कहा गया है कि ""उच्च रक्तचाप का नियंत्रण व्यापक हृदय जोखिम प्रबंधन का हिस्सा होना चाहिए, जिसमें उचित रूप से लिपिड नियंत्रण, मधुमेह प्रबंधन, एंटीथ्रॉम्बोटिक थेरेपी, **धूम्रपान बंद**, व्यायाम और सीमित सोडियम सेवन शामिल है।""

इसके अतिरिक्त, संदर्भ कई मामलों में धूम्रपान को कोरोनरी हृदय रोग के लिए एक जोखिम कारक के रूप में पहचानता है, और इंगित करता है कि हृदय-स्वस्थ जीवनशैली में बदलाव करने से हृदय रोगों के जोखिम को कम करने में मदद मिल सकती है। धूम्रपान बंद करना इन हृदय-स्वस्थ जीवनशैली संशोधनों का एक प्रमुख घटक है।",31.4115948677063,8.17154335975647,0.03304004669189453,0.5013964176177979,31.378554821014404,7.670146942138672,claude-sonnet-4-5-20250929,True
धूम्रपान छोड़ने का हृदय रोग के जोखिम पर क्या प्रभाव पड़ता है?,hindi,What effect does quitting smoking have on heart disease risk?,". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking","Based on the information provided:

**Quitting smoking reduces the risk of heart disease.**

Key Points:

1. **Smoking is a risk factor for heart disease**: Smoking cigarettes increases blood pressure and increases the risk of heart attack and stroke.

2. **Benefits of Stopping Smoking**: If you smoke, quitting will reduce your risk of heart disease.

3. **Recommendation**: 
   - If you don't smoke, don't start
   - If you smoke, talk to your healthcare provider about quitting, who can help you find the best way for you

In short, quitting smoking is very beneficial for heart health and reduces the risk of heart disease to a great extent.","Based on the provided medical information, **quitting smoking lowers your risk of heart disease**.

The context specifically states that cigarette smoking raises blood pressure and puts you at higher risk of heart attack and stroke. When you quit smoking, you reduce these cardiovascular risks.

The medical sources emphasize that:
- Cigarette smoking increases the risk of serious cardiovascular events
- Not smoking is an important preventive measure for heart disease
- If you currently smoke, quitting will lower your risk of heart disease
- Healthcare providers can help you find the best method to quit smoking

The information also notes that smoking is linked to heart disease in multiple ways, including raising blood pressure and potentially triggering heart attacks, making smoking cessation a crucial step in reducing cardiovascular disease risk.",". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking
---
INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking",Healthcare assistant prompt,"प्रदान की गई जानकारी के आधार पर:

**धूम्रपान छोड़ने से हृदय रोग का जोखिम कम हो जाता है।**

मुख्य बिंदु:

1. **धूम्रपान हृदय रोग के लिए एक जोखिम कारक है**: सिगरेट पीने से रक्तचाप बढ़ता है और दिल के दौरे (heart attack) और स्ट्रोक का खतरा अधिक हो जाता है।

2. **धूम्रपान बंद करने के लाभ**: यदि आप धूम्रपान करते हैं, तो इसे छोड़ने से हृदय रोग का जोखिम कम हो जाएगा।

3. **सिफारिश**: 
   - यदि आप धूम्रपान नहीं करते हैं, तो शुरू न करें
   - यदि आप धूम्रपान करते हैं, तो छोड़ने के लिए अपने स्वास्थ्य सेवा प्रदाता से बात करें, जो आपके लिए सबसे अच्छा तरीका खोजने में मदद कर सकते हैं

संक्षेप में, धूम्रपान छोड़ना हृदय स्वास्थ्य के लिए बहुत फायदेमंद है और हृदय रोग के जोखिम को काफी हद तक कम करता है।","प्रदान की गई चिकित्सा जानकारी के आधार पर, **धूम्रपान छोड़ने से हृदय रोग का खतरा कम हो जाता है**।

संदर्भ विशेष रूप से बताता है कि सिगरेट पीने से रक्तचाप बढ़ जाता है और आपको दिल का दौरा और स्ट्रोक का खतरा बढ़ जाता है। जब आप धूम्रपान छोड़ देते हैं, तो आप इन हृदय संबंधी खतरों को कम कर देते हैं।

चिकित्सा सूत्र इस बात पर जोर देते हैं:
- सिगरेट पीने से गंभीर हृदय संबंधी घटनाओं का खतरा बढ़ जाता है
- धूम्रपान न करना हृदय रोग के लिए एक महत्वपूर्ण निवारक उपाय है
- यदि आप वर्तमान में धूम्रपान करते हैं, तो छोड़ने से हृदय रोग का खतरा कम हो जाएगा
- स्वास्थ्य सेवा प्रदाता आपको धूम्रपान छोड़ने का सर्वोत्तम तरीका ढूंढने में मदद कर सकते हैं

जानकारी में यह भी कहा गया है कि धूम्रपान कई तरह से हृदय रोग से जुड़ा हुआ है, जिसमें रक्तचाप बढ़ना और संभावित रूप से दिल का दौरा पड़ना शामिल है, जिससे हृदय रोग के जोखिम को कम करने के लिए धूम्रपान बंद करना एक महत्वपूर्ण कदम है।",9.940617561340332,7.166423797607422,0.032126426696777344,0.549149751663208,9.908491134643555,6.617274045944214,claude-sonnet-4-5-20250929,True
हृदय रोग के जोखिम को कम करने के लिए महिलाओं के लिए शराब सेवन के दिशा-निर्देश क्या हैं?,hindi,What are the alcohol consumption guidelines for women to reduce heart disease risk?,". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","The information provided does not provide general guidelines for alcohol consumption to reduce heart disease risk for women.

The information given is only about specific warnings for patients taking varenicline (a quit smoking medicine). It states that:

**Alcohol Interactions with Varenicline:** Increased effects of alcohol have been reported. Patients are advised to limit their alcohol consumption until they know how varenicline affects them.

This is not a guideline for alcohol consumption for general heart health, but rather a caution with this particular medication.","Based on the provided context, I cannot answer your question about alcohol consumption guidelines for women to reduce heart disease risk. 

The context only discusses varenicline (a smoking cessation medication) and its interaction with alcohol, specifically warning that increased effects of alcohol have been reported with this medication. It does not contain information about general alcohol consumption guidelines for women or recommendations for reducing heart disease risk.

To get accurate information about alcohol consumption guidelines for women and heart disease prevention, you would need to consult other medical resources or speak with a healthcare provider.",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"प्रदान की गई जानकारी में महिलाओं के लिए हृदय रोग के जोखिम को कम करने के लिए शराब सेवन के सामान्य दिशा-निर्देश नहीं दिए गए हैं।

दी गई जानकारी केवल varenicline (एक धूम्रपान छोड़ने की दवा) लेने वाले मरीजों के लिए विशिष्ट चेतावनी के बारे में है। इसमें बताया गया है कि:

**Varenicline के साथ शराब की परस्पर क्रिया:** शराब के प्रभाव में वृद्धि की रिपोर्ट की गई है। मरीजों को सलाह दी जाती है कि जब तक वे यह नहीं जान लेते कि varenicline उन्हें कैसे प्रभावित करता है, तब तक वे अपने शराब की खपत को कम करें।

यह सामान्य हृदय स्वास्थ्य के लिए शराब सेवन के दिशा-निर्देश नहीं है, बल्कि इस विशेष दवा के साथ एक सावधानी है।","दिए गए संदर्भ के आधार पर, मैं हृदय रोग के जोखिम को कम करने के लिए महिलाओं के लिए शराब के सेवन संबंधी दिशानिर्देशों के बारे में आपके प्रश्न का उत्तर नहीं दे सकता। 

संदर्भ में केवल वैरेनिकलाइन (धूम्रपान बंद करने की दवा) और शराब के साथ इसकी अंतःक्रिया पर चर्चा की गई है, विशेष रूप से चेतावनी दी गई है कि इस दवा के साथ शराब के प्रभाव में वृद्धि दर्ज की गई है। इसमें महिलाओं के लिए सामान्य शराब सेवन दिशानिर्देशों या हृदय रोग के जोखिम को कम करने के लिए सिफारिशों के बारे में जानकारी नहीं है।

महिलाओं के लिए शराब सेवन दिशानिर्देशों और हृदय रोग की रोकथाम के बारे में सटीक जानकारी प्राप्त करने के लिए, आपको अन्य चिकित्सा संसाधनों से परामर्श करने या स्वास्थ्य सेवा प्रदाता से बात करने की आवश्यकता होगी।",9.55275583267212,6.308037519454956,0.06370973587036133,0.5655443668365479,9.489046096801758,5.742493152618408,claude-sonnet-4-5-20250929,True
मेपिवाकेन हाइड्रोक्लोराइड का उपयोग किस लिए किया जाता है?,hindi,What is mepivacaine hydrochloride used for?,"CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells. Mechanism of action Angina: The precise mechanism of action of verapamil hydrochloride as an antianginal agent remains to be fully determined, but includes the following two mechanisms: 1 . Relaxation and prevention of coronary artery spasm: Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride","There is no information about Mepivacaine Hydrochloride in the reference materials provided. 

The information given contains details of the following medicines only:
- Amitriptyline hydrochloride (antidepressant)
- Glucocorticoids (anti-inflammatory drugs)
- Verapamil hydrochloride (calcium channel blocker)

Appropriate medical reference material will be required to provide accurate information about the use of mepivacaine hydrochloride.","Based on the provided context, mepivacaine hydrochloride is a local anesthetic used for:

1. **Local infiltration**
2. **Peripheral nerve block**
3. **Caudal epidural blocks**
4. **Lumbar epidural blocks**

It is available as sterile isotonic solutions in concentrations of 1%, 1.5%, and 2% for injection. Mepivacaine hydrochloride belongs to the amide-type local anesthetics class and is chemically and pharmacologically related to other medications in this category.","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibito
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulat","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so",Healthcare assistant prompt,"प्रदान की गई संदर्भ सामग्री में मेपिवाकेन हाइड्रोक्लोराइड (Mepivacaine Hydrochloride) के बारे में कोई जानकारी नहीं है। 

दी गई जानकारी में केवल निम्नलिखित दवाओं का विवरण है:
- एमिट्रिप्टिलाइन हाइड्रोक्लोराइड (अवसादरोधी दवा)
- ग्लूकोकॉर्टिकॉइड्स (सूजन-रोधी दवाएं)
- वेरापामिल हाइड्रोक्लोराइड (कैल्शियम चैनल ब्लॉकर)

मेपिवाकेन हाइड्रोक्लोराइड के उपयोग के बारे में सटीक जानकारी देने के लिए उपयुक्त चिकित्सा संदर्भ सामग्री की आवश्यकता होगी।","दिए गए संदर्भ के आधार पर, मेपिवाकेन हाइड्रोक्लोराइड एक स्थानीय संवेदनाहारी है जिसका उपयोग निम्न के लिए किया जाता है:

1. **स्थानीय घुसपैठ**
2. **परिधीय तंत्रिका ब्लॉक**
3. **कॉडल एपिड्यूरल ब्लॉक**
4. **लम्बर एपिड्यूरल ब्लॉक**

यह इंजेक्शन के लिए 1%, 1.5% और 2% की सांद्रता में बाँझ आइसोटोनिक समाधान के रूप में उपलब्ध है। मेपिवाकेन हाइड्रोक्लोराइड एमाइड-प्रकार के स्थानीय एनेस्थेटिक्स वर्ग से संबंधित है और रासायनिक और औषधीय रूप से इस श्रेणी की अन्य दवाओं से संबंधित है।",7.856321573257446,6.209764003753662,0.044295549392700195,0.45159173011779785,7.812026023864746,5.758172273635864,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड का संरचनात्मक सूत्र क्या है?,hindi,What is the structural formula of meperidine hydrochloride?,". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. It has the following structural formula: Codeine phosphate (7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1)(salt) hemihydrate) is an opioid agonist. It has the following structural formula: Chemical structure of Butalbital Chemical structure of Acetaminophen Chemical structure of Caffeine Chemical structure of Codeine Phosphate Inactive Ingredients: black iron oxide, colloidal silicon dioxide, FD&C Blue #1, gelatin, magnesium stearate, pregelatinized corn starch, and titanium dioxide.

DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure","There is no information regarding the structural formula of Meperidine Hydrochloride in the reference provided.

Only the following compounds are reported in the reference:
- Bupropion and its metabolites
- codeine phosphate
- butalbital
- Acetaminophen
- caffeine
- Mepivacaine Hydrochloride

Please note that mepivacaine hydrochloride and meperidine hydrochloride are two different medicines.","I cannot provide the structural formula of meperidine hydrochloride based on the provided context, as the context does not contain information about meperidine hydrochloride.

The context discusses **mepivacaine hydrochloride** (not meperidine), which is a different medication. Mepivacaine hydrochloride is described as 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride with the molecular formula C₁₅H₂₂N₂O·HCl.

If you need information about meperidine hydrochloride specifically, please provide relevant source material about that medication.",". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. It has the following structural formula: Codeine phosphate (7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1)(salt) hemihydrate) is an opioid agonist. It has the following 
---
DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C ","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition ",Healthcare assistant prompt,"प्रदान किए गए संदर्भ में मेपेरिडाइन हाइड्रोक्लोराइड (Meperidine Hydrochloride) के संरचनात्मक सूत्र के बारे में कोई जानकारी नहीं है।

संदर्भ में केवल निम्नलिखित यौगिकों की जानकारी दी गई है:
- ब्यूप्रोपियन और इसके मेटाबोलाइट्स
- कोडीन फॉस्फेट
- ब्यूटालबिटल
- एसिटामिनोफेन
- कैफीन
- मेपिवाकेन हाइड्रोक्लोराइड (Mepivacaine Hydrochloride)

कृपया ध्यान दें कि मेपिवाकेन हाइड्रोक्लोराइड और मेपेरिडाइन हाइड्रोक्लोराइड दो अलग-अलग दवाएं हैं।","मैं दिए गए संदर्भ के आधार पर मेपरिडीन हाइड्रोक्लोराइड का संरचनात्मक सूत्र प्रदान नहीं कर सकता, क्योंकि संदर्भ में मेपरिडीन हाइड्रोक्लोराइड के बारे में जानकारी नहीं है।

संदर्भ में **मेपिवाकेन हाइड्रोक्लोराइड** (मेपरिडीन नहीं) पर चर्चा की गई है, जो एक अलग दवा है। मेपिवाकेन हाइड्रोक्लोराइड को आणविक सूत्र C₁₅H₂₂N₂O·HCl के साथ 2-पाइपरिडीनकारबॉक्सामाइड, N-(2,6-डाइमिथाइलफिनाइल)-1-मिथाइल-, मोनोहाइड्रोक्लोराइड के रूप में वर्णित किया गया है।

यदि आपको विशेष रूप से मेपरिडीन हाइड्रोक्लोराइड के बारे में जानकारी चाहिए, तो कृपया उस दवा के बारे में प्रासंगिक स्रोत सामग्री प्रदान करें।",8.192269802093506,7.636174440383911,0.012477397918701172,0.4868769645690918,8.179792404174805,7.149297475814819,claude-sonnet-4-5-20250929,True
स्थानीय एनेस्थेटिक्स की क्रिया में प्लाज्मा प्रोटीन की क्या भूमिका होती है?,hindi,What role do plasma proteins play in the action of local anesthetics?,". In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study determining the effect of other therapeutic agents on the in vitro binding of carbon-14 labeled etoposide to human serum proteins, only phenylbutazone, sodium salicylate, and aspirin displaced protein-bound etoposide at concentrations achieved in vivo . Etoposide binding ratio correlates directly with serum albumin in patients with cancer and in normal volunteers. The unbound fraction of etoposide significantly correlated with bilirubin in a population of cancer patients. Data have suggested a significant Inverse correlation between serum albumin concentration and free fraction of etoposide

. chemical structure Mechanism of Action The mechanism of action of captopril tablets have not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril tablets prevent the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase

. chemical structure Mechanism of Action The mechanism of action of captopril tablets have not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril tablets prevent the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion",". It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from human adults: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2′,6′-pipecoloxylidide). Mepivacaine does not ordinarily produce irritation or tissue damage, and does not cause methemoglobinemia when administered in recommended doses and concentrations.

. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacaine is approximately 75% bound to plasma proteins. The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation. Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient

. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion. Metabolism Bupropion is extensively metabolized in humans. Three metabolites are active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion

. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion. Metabolism Bupropion is extensively metabolized in humans. Three metabolites are active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion

. In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study determining the effect of other therapeutic agents on the in vitro binding of carbon-14 labeled etoposide to human serum proteins, only phenylbutazone, sodium salicylate, and aspirin displaced protein-bound etoposide at concentrations achieved in vivo . Etoposide binding ratio correlates directly with serum albumin in patients with cancer and in normal volunteers. The unbound fraction of etoposide significantly correlated with bilirubin in a population of cancer patients. Data have suggested a significant Inverse correlation between serum albumin concentration and free fraction of etoposide","There is no information about local anesthetics in the reference provided. 

The reference given contains information only about the following medicines:
- Etoposide (a cancer drug)
- Captopril (high blood pressure medicine)
- Bupropion (an antidepressant drug)

Therefore I cannot answer based on the context given regarding the role of plasma proteins in the action of local anesthetics.

If you require information on this topic, please provide references to specific medical sources or documents related to local anesthetics.","Based on the provided context, plasma proteins play a crucial role in the action of local anesthetics, specifically in their distribution and placental transfer:

**Key Role: Limiting Placental Transfer**

Plasma protein binding directly affects the transfer of local anesthetics across the placenta. According to the context:

- **Fetal/maternal ratios of local anesthetics are inversely related to the degree of plasma protein binding**
- Only the **free, unbound drug is available for placental transfer**
- Using mepivacaine as an example, it is approximately **75% bound to plasma proteins**, which limits the amount of drug that can cross the placenta

**Mechanism:**

When a local anesthetic is bound to plasma proteins, it becomes temporarily ""trapped"" in the maternal circulation and cannot readily cross the placental barrier. Only the unbound (free) fraction of the drug can transfer to the fetal circulation. Therefore, drugs with higher protein binding have lower fetal exposure.

**Clinical Significance:**

This protein binding characteristic is important for:
- Reducing fetal drug exposure during procedures requiring local anesthesia in pregnant patients
- Understanding drug distribution patterns
- Predicting potential fetal effects

The extent of placental transfer is also influenced by other factors mentioned in the context, including the drug's degree of ionization and lipid solubility.",". In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study dete
---
. chemical structure Mechanism of Action The mechanism of action of captopril tablets have not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result prim
---
. chemical structure Mechanism of Action The mechanism of action of captopril tablets have not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result prim
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion",". It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been ide
---
. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacain
---
. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar 
---
. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar 
---
. In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study dete",Healthcare assistant prompt,"प्रदान किए गए संदर्भ में स्थानीय एनेस्थेटिक्स (local anesthetics) के बारे में कोई जानकारी नहीं है। 

दिए गए संदर्भ में केवल निम्नलिखित दवाओं के बारे में जानकारी है:
- Etoposide (एक कैंसर की दवा)
- Captopril (उच्च रक्तचाप की दवा)
- Bupropion (एक अवसादरोधी दवा)

इसलिए मैं स्थानीय एनेस्थेटिक्स की क्रिया में प्लाज्मा प्रोटीन की भूमिका के बारे में दिए गए संदर्भ के आधार पर उत्तर नहीं दे सकता।

यदि आपको इस विषय पर जानकारी चाहिए, तो कृपया स्थानीय एनेस्थेटिक्स से संबंधित विशिष्ट चिकित्सा स्रोतों या दस्तावेजों का संदर्भ प्रदान करें।","दिए गए संदर्भ के आधार पर, प्लाज्मा प्रोटीन स्थानीय एनेस्थेटिक्स की कार्रवाई में महत्वपूर्ण भूमिका निभाते हैं, विशेष रूप से उनके वितरण और प्लेसेंटल स्थानांतरण में:

**मुख्य भूमिका: प्लेसेंटल स्थानांतरण को सीमित करना**

प्लाज़्मा प्रोटीन बाइंडिंग सीधे प्लेसेंटा में स्थानीय एनेस्थेटिक्स के स्थानांतरण को प्रभावित करता है। प्रसंग के अनुसार:

- **स्थानीय एनेस्थेटिक्स का भ्रूण/मातृ अनुपात प्लाज्मा प्रोटीन बाइंडिंग की डिग्री से विपरीत रूप से संबंधित होता है**
- प्लेसेंटल ट्रांसफर के लिए केवल **निःशुल्क, अनबाउंड दवा उपलब्ध है**
- उदाहरण के तौर पर मेपिवाकेन का उपयोग करते हुए, यह लगभग **75% प्लाज्मा प्रोटीन से बंधा हुआ है**, जो प्लेसेंटा को पार करने वाली दवा की मात्रा को सीमित करता है

**तंत्र:**

जब एक स्थानीय संवेदनाहारी प्लाज्मा प्रोटीन से बंधी होती है, तो यह अस्थायी रूप से मातृ परिसंचरण में ""फंस"" जाती है और प्लेसेंटल बाधा को आसानी से पार नहीं कर पाती है। दवा का केवल अनबाउंड (मुक्त) अंश ही भ्रूण के परिसंचरण में स्थानांतरित हो सकता है। इसलिए, उच्च प्रोटीन बाइंडिंग वाली दवाओं का भ्रूण पर कम प्रभाव पड़ता है।

**नैदानिक महत्व:**

यह प्रोटीन बाइंडिंग विशेषता इसके लिए महत्वपूर्ण है:
- गर्भवती रोगियों में स्थानीय संज्ञाहरण की आवश्यकता वाली प्रक्रियाओं के दौरान भ्रूण के दवा के जोखिम को कम करना
- दवा वितरण पैटर्न को समझना
- संभावित भ्रूण प्रभावों की भविष्यवाणी करना

अपरा स्थानांतरण की सीमा संदर्भ में उल्लिखित अन्य कारकों से भी प्रभावित होती है, जिसमें दवा की आयनीकरण की डिग्री और लिपिड घुलनशीलता शामिल है।",7.773043394088745,10.808462619781494,0.02867269515991211,0.48201990127563477,7.744370698928833,10.32644271850586,claude-sonnet-4-5-20250929,True
कौन सी मेपिवाकेन हाइड्रोक्लोराइड की सांद्रता पूर्ण संवेदी और मोटर ब्लॉक प्रदान करती है?,hindi,What concentration of mepivacaine hydrochloride provides complete sensory and motor block?,". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT 1B/1D receptor. Elimination The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10-mg oral administration of 14 C-rizatriptan. Following oral administration of 14 C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism

. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT 1B/1D receptor. Elimination The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10-mg oral administration of 14 C-rizatriptan. Following oral administration of 14 C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from human adults: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2′,6′-pipecoloxylidide). Mepivacaine does not ordinarily produce irritation or tissue damage, and does not cause methemoglobinemia when administered in recommended doses and concentrations.

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure","The information provided does not contain any details about Mepivacaine Hydrochloride. The given material contains only information about the drugs bupropion and rizatriptan, relating to their metabolites and excretion.

Please consult your doctor or pharmacist for information regarding the concentration of mepivacaine hydrochloride that provides complete sensory and motor block.","Based on the provided context, **2% concentration of mepivacaine hydrochloride** will produce complete sensory and motor block of any nerve group.

The context also notes that the 1.5% solution will provide extensive and often complete motor block, but the 2% concentration is specifically stated to produce complete sensory AND motor block.",". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatript
---
. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatript
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been ide
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont",Healthcare assistant prompt,"प्रदान की गई जानकारी में मेपिवाकेन हाइड्रोक्लोराइड (Mepivacaine Hydrochloride) के बारे में कोई विवरण नहीं है। दी गई सामग्री में केवल bupropion और rizatriptan दवाओं के बारे में जानकारी है, जो उनके मेटाबोलाइट्स और उत्सर्जन से संबंधित है।

मेपिवाकेन हाइड्रोक्लोराइड की सांद्रता जो पूर्ण संवेदी और मोटर ब्लॉक प्रदान करती है, इसके बारे में जानकारी प्राप्त करने के लिए कृपया अपने चिकित्सक या फार्मासिस्ट से परामर्श करें।","दिए गए संदर्भ के आधार पर, **मेपिवाकेन हाइड्रोक्लोराइड की 2% सांद्रता** किसी भी तंत्रिका समूह के पूर्ण संवेदी और मोटर ब्लॉक का उत्पादन करेगी।

संदर्भ यह भी नोट करता है कि 1.5% समाधान व्यापक और अक्सर पूर्ण मोटर ब्लॉक प्रदान करेगा, लेकिन 2% एकाग्रता विशेष रूप से पूर्ण संवेदी और मोटर ब्लॉक का उत्पादन करने के लिए कहा गया है।",6.958580255508423,5.542058944702148,0.020804405212402344,0.4989192485809326,6.9377758502960205,5.043139696121216,claude-sonnet-4-5-20250929,True
मेपिवाकेन द्वारा प्रदान की गई एनेस्थीसिया आमतौर पर सर्जरी के लिए कितनी देर तक पर्याप्त होती है?,hindi,How long is the anesthesia provided by mepivacaine usually sufficient for surgery?,". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. Treatment should begin with the intravenous administration of 5 mg atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. Atenolol injection should be administered under carefully controlled conditions including monitoring of blood pressure, heart rate, and electrocardiogram. Dilutions of atenolol injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and Dextrose Injection may be used. These admixtures are stable for 48 hours if they are not used immediately. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. Thereafter, atenolol can be given orally either 100 mg once daily or 50 mg twice a day for a further 6 to 9 days or until discharge from the hospital

. Treatment should begin with the intravenous administration of 5 mg atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. Atenolol injection should be administered under carefully controlled conditions including monitoring of blood pressure, heart rate, and electrocardiogram. Dilutions of atenolol injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and Dextrose Injection may be used. These admixtures are stable for 48 hours if they are not used immediately. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. Thereafter, atenolol can be given orally either 100 mg once daily or 50 mg twice a day for a further 6 to 9 days or until discharge from the hospital

. Captopril tablets should generally be used in conjunction with a diuretic and digitalis. Captopril tablets therapy must be initiated under very close medical supervision. Left Ventricular Dysfunction After Myocardial Infarction The recommended dose for long-term use in patients following a myocardial infarction is a target maintenance dose of 50 mg t.i.d. Therapy may be initiated as early as three days following a myocardial infarction. After a single dose of 6.25 mg, captopril tablets therapy should be initiated at 12.5 mg t.i.d. Captopril tablets should then be increased to 25 mg t.i.d. during the next several days and to a target dose of 50 mg t.i.d. over the next several weeks as tolerated (see CLINICAL PHARMACOLOGY). Captopril tablets may be used in patients treated with other post-myocardial infarction therapies, e.g., thrombolytics, aspirin, beta blockers

. Captopril tablets should generally be used in conjunction with a diuretic and digitalis. Captopril tablets therapy must be initiated under very close medical supervision. Left Ventricular Dysfunction After Myocardial Infarction The recommended dose for long-term use in patients following a myocardial infarction is a target maintenance dose of 50 mg t.i.d. Therapy may be initiated as early as three days following a myocardial infarction. After a single dose of 6.25 mg, captopril tablets therapy should be initiated at 12.5 mg t.i.d. Captopril tablets should then be increased to 25 mg t.i.d. during the next several days and to a target dose of 50 mg t.i.d. over the next several weeks as tolerated (see CLINICAL PHARMACOLOGY). Captopril tablets may be used in patients treated with other post-myocardial infarction therapies, e.g., thrombolytics, aspirin, beta blockers",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. A dilute concentration of epinephrine (1:200,000 or 5 μ g/mL) usually reduces the rate of absorption and plasma concentration of mepivacaine, however, it has been reported that vasoconstrictors do not significantly prolong anesthesia with mepivacaine. Onset of anesthesia with mepivacaine is rapid, the time of onset for sensory block ranging from about 3 to 20 minutes depending upon such factors as the anesthetic technique, the type of block, the concentration of the solution, and the individual patient. The degree of motor blockade produced is dependent on the concentration of the solution. A 0.5% solution will be effective in small superficial nerve blocks while the 1% concentration will block sensory and sympathetic conduction without loss of motor function. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group

. For Support of Anesthesia Repeated slow intravenous injections of fractional doses (e.g., 10 mg/mL) or by a continuous intravenous infusion of a more dilute solution (e.g., 1 mg/mL) should be used. The dose should be titrated to the needs of the patient and will depend on the premedication and type of anesthesia being employed, the characteristics of the particular patient and the nature and duration of the operative procedure. Elderly patients should usually be given meperidine at the lower end of the dose range and observed closely. For Obstetrical Analgesia The usual dosage is 50 to 100 mg intramuscularly or subcutaneously when pain becomes regular and may be repeated at 1 to 3 hour intervals. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

. For Support of Anesthesia Repeated slow intravenous injections of fractional doses (e.g., 10 mg/mL) or by a continuous intravenous infusion of a more dilute solution (e.g., 1 mg/mL) should be used. The dose should be titrated to the needs of the patient and will depend on the premedication and type of anesthesia being employed, the characteristics of the particular patient and the nature and duration of the operative procedure. Elderly patients should usually be given meperidine at the lower end of the dose range and observed closely. For Obstetrical Analgesia The usual dosage is 50 to 100 mg intramuscularly or subcutaneously when pain becomes regular and may be repeated at 1 to 3 hour intervals. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

CLINICAL PHARMACOLOGY: 1.2 CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset and duration of anesthesia: The onset of action is rapid. For retrobulbar injection, 4 mL of 4% Lidocaine Hydrochloride Injection, USP provides an average duration of action of 1 to 1½ hours. This duration may be extended for ophthalmic surgery by the addition of epinephrine, the usual recommended dilution being 1:50,000 to 1:100,000. Hemodynamics: Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. The net effect is normally a modest hypotension when the recommended dosages are not exceeded","As per the information provided, anesthesia provided by Mepivacaine is usually sufficient for **2 to 2.5 hours of surgery**.

It is important to note that the duration of anesthesia depends on several factors such as:
- Technology and type of block
- concentration of medicine
- individual variation","Based on the provided context, mepivacaine normally provides anesthesia that is adequate for **2 to 2½ hours of surgery**.

The context also notes that the duration of anesthesia varies depending on several factors including:
- The technique and type of block used
- The concentration of the solution
- Individual patient characteristics

Additionally, while epinephrine can reduce the rate of absorption and plasma concentration of mepivacaine, it has been reported that vasoconstrictors do not significantly prolong the anesthetic duration with mepivacaine.",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. Treatment should begin with the intravenous administration of 5 mg atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. Atenolol injection should be administered 
---
. Treatment should begin with the intravenous administration of 5 mg atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. Atenolol injection should be administered 
---
. Captopril tablets should generally be used in conjunction with a diuretic and digitalis. Captopril tablets therapy must be initiated under very close medical supervision. Left Ventricular Dysfunctio
---
. Captopril tablets should generally be used in conjunction with a diuretic and digitalis. Captopril tablets therapy must be initiated under very close medical supervision. Left Ventricular Dysfunctio",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. A dilute concentration of epinephrine (1:200,000 or 5 μ g/mL) usually reduces the rate of absorption and plasma concentration of mepivacaine, however, it has been reported that vasoconstrictors do n
---
. For Support of Anesthesia Repeated slow intravenous injections of fractional doses (e.g., 10 mg/mL) or by a continuous intravenous infusion of a more dilute solution (e.g., 1 mg/mL) should be used. 
---
. For Support of Anesthesia Repeated slow intravenous injections of fractional doses (e.g., 10 mg/mL) or by a continuous intravenous infusion of a more dilute solution (e.g., 1 mg/mL) should be used. 
---
CLINICAL PHARMACOLOGY: 1.2 CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, ",Healthcare assistant prompt,"प्रदान की गई जानकारी के अनुसार, मेपिवाकेन (Mepivacaine) द्वारा प्रदान की गई एनेस्थीसिया आमतौर पर **2 से 2.5 घंटे की सर्जरी के लिए पर्याप्त होती है**।

यह ध्यान रखना महत्वपूर्ण है कि एनेस्थीसिया की अवधि कई कारकों पर निर्भर करती है जैसे:
- तकनीक और ब्लॉक का प्रकार
- दवा की सांद्रता (concentration)
- व्यक्तिगत भिन्नता","दिए गए संदर्भ के आधार पर, मेपिवाकेन आम तौर पर एनेस्थीसिया प्रदान करता है जो **2 से 2½ घंटे की सर्जरी** के लिए पर्याप्त है।

संदर्भ में यह भी कहा गया है कि एनेस्थीसिया की अवधि कई कारकों के आधार पर भिन्न होती है, जिनमें शामिल हैं:
- इस्तेमाल की गई तकनीक और ब्लॉक का प्रकार
- समाधान की एकाग्रता
- व्यक्तिगत रोगी विशेषताएँ

इसके अतिरिक्त, जबकि एपिनेफ्रिन मेपिवाकेन के अवशोषण की दर और प्लाज्मा एकाग्रता को कम कर सकता है, यह बताया गया है कि वैसोकॉन्स्ट्रिक्टर्स मेपिवाकेन के साथ संवेदनाहारी अवधि को महत्वपूर्ण रूप से नहीं बढ़ाते हैं।",5.930700302124023,6.991064548492432,0.0351564884185791,0.5244975090026855,5.895543813705444,6.466567039489746,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन का पीएच रेंज क्या है?,hindi,What is the pH range of meperidine hydrochloride injection?,". N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT 1B/1D receptor. Elimination The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10-mg oral administration of 14 C-rizatriptan. Following oral administration of 14 C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism

. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT 1B/1D receptor. Elimination The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10-mg oral administration of 14 C-rizatriptan. Following oral administration of 14 C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism

. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject

. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject

. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject",". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride","There is no information regarding the pH range of meperidine hydrochloride injection in the reference provided. The reference only provides information about the drugs rizatriptan and glimepiride, there are no details about meperidine hydrochloride.","Based on the provided FDA information, the pH range of Meperidine Hydrochloride Injection, USP is **3.5-6.0**.

The injection is buffered with acetic acid-sodium acetate to maintain this pH range.",". N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatript
---
. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatript
---
. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cycloh
---
. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cycloh
---
. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose. The major metabolites are the cycloh",". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so",Healthcare assistant prompt,"प्रदान किए गए संदर्भ में मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन के पीएच रेंज के बारे में कोई जानकारी नहीं है। संदर्भ में केवल rizatriptan और glimepiride दवाओं के बारे में जानकारी दी गई है, मेपेरिडाइन हाइड्रोक्लोराइड के बारे में कोई विवरण नहीं है।","प्रदान की गई एफडीए जानकारी के आधार पर, मेपरिडीन हाइड्रोक्लोराइड इंजेक्शन, यूएसपी की पीएच रेंज **3.5-6.0** है।

इस पीएच रेंज को बनाए रखने के लिए इंजेक्शन को एसिटिक एसिड-सोडियम एसीटेट के साथ बफर किया जाता है।",5.045518398284912,5.629549503326416,0.029752731323242188,0.4531362056732178,5.01576566696167,5.176413297653198,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन के प्रशासन के रूप क्या हैं?,hindi,What are the forms of administration of meperidine hydrochloride injection?,". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

. The pharmacological action of allopurinol is generally believed to be mediated by its oxypurinol metabolite. Effect on Hypoxanthine and Xanthine Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol tablets and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol tablets for treatment of hyperuricemia is usually in the range of 0.3 mg/dL to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol tablets

CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells. Mechanism of action Angina: The precise mechanism of action of verapamil hydrochloride as an antianginal agent remains to be fully determined, but includes the following two mechanisms: 1 . Relaxation and prevention of coronary artery spasm: Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced",". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride","I'm sorry, but the information provided does not contain any details regarding the forms of administration of meperidine hydrochloride injection. 

The given material contains information only about the following medicines:
- Bupropion
- Amitriptyline hydrochloride
- Allopurinol
-Atorvastatin
- Verapamil hydrochloride

To provide information about meperidine hydrochloride injection, I will need specific medical documentation related to that medicine.","Based on the provided FDA information, Meperidine Hydrochloride Injection, USP can be administered via the following routes:

1. **Intramuscular (IM)**
2. **Subcutaneous (SC)**
3. **Slow intravenous (IV)**

The medication is described as ""a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic."" It is important to note that when given intravenously, it must be administered slowly.",". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibito
---
. The pharmacological action of allopurinol is generally believed to be mediated by its oxypurinol metabolite. Effect on Hypoxanthine and Xanthine Reutilization of both hypoxanthine and xanthine for n
---
CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-met
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulat",". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so",Healthcare assistant prompt,"मुझे खेद है, लेकिन प्रदान की गई जानकारी में मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन के प्रशासन के रूपों के बारे में कोई विवरण नहीं है। 

दी गई सामग्री में केवल निम्नलिखित दवाओं की जानकारी है:
- ब्यूप्रोपियन (Bupropion)
- एमिट्रिप्टिलाइन हाइड्रोक्लोराइड (Amitriptyline hydrochloride)
- एलोप्यूरिनॉल (Allopurinol)
- एटोरवास्टेटिन (Atorvastatin)
- वेरापामिल हाइड्रोक्लोराइड (Verapamil hydrochloride)

मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन के बारे में जानकारी देने के लिए मुझे उस दवा से संबंधित विशिष्ट चिकित्सा दस्तावेज़ की आवश्यकता होगी।","प्रदान की गई एफडीए जानकारी के आधार पर, मेपरिडीन हाइड्रोक्लोराइड इंजेक्शन, यूएसपी को निम्नलिखित मार्गों से प्रशासित किया जा सकता है:

1. **इंट्रामस्क्युलर (आईएम)**
2. **उपचर्म (एससी)**
3. **धीमी अंतःशिरा (IV)**

दवा को ""मादक दर्दनाशक के रूप में इंट्रामस्क्युलर, चमड़े के नीचे या धीमी अंतःशिरा उपयोग के लिए एक बाँझ समाधान"" के रूप में वर्णित किया गया है। यह ध्यान रखना महत्वपूर्ण है कि जब अंतःशिरा दिया जाता है, तो इसे धीरे-धीरे प्रशासित किया जाना चाहिए।",8.828157186508179,6.419088125228882,0.05010080337524414,0.540015697479248,8.778056383132935,5.879072427749634,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड का गलनांक क्या है?,hindi,What is the melting point of meperidine hydrochloride?,". Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users. First-pass metabolism of EE involves formation of EE-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed EE by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of EE hydroxylation. Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation. Excretion About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates

. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users. First-pass metabolism of EE involves formation of EE-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed EE by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of EE hydroxylation. Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation. Excretion About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates

. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below","There is no information regarding the melting point of meperidine hydrochloride in the reference provided. 

Only information regarding the metabolism and excretion processes of levonorgestrel, ethinyl estradiol (EE), and bupropion is provided in the given reference. There is no mention of the chemical properties or melting point of meperidine hydrochloride.","Based on the provided context, I cannot answer this question. The context contains information about **mepivacaine hydrochloride** (a local anesthetic), not meperidine hydrochloride. These are two different medications.

The context describes mepivacaine hydrochloride as ""a white, crystalline odorless powder, soluble in water"" but does not provide information about its melting point. Additionally, no information about meperidine hydrochloride is included in the provided text.

To answer your question about the melting point of meperidine hydrochloride, I would need access to documentation specifically about that medication.",". Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for 
---
. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for 
---
. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H ",Healthcare assistant prompt,"प्रदान किए गए संदर्भ में मेपेरिडाइन हाइड्रोक्लोराइड के गलनांक (melting point) के बारे में कोई जानकारी नहीं है। 

दिए गए संदर्भ में केवल लेवोनोर्जेस्ट्रेल (Levonorgestrel), एथिनिल एस्ट्राडियोल (EE), और ब्यूप्रोपियन (Bupropion) की चयापचय (metabolism) और उत्सर्जन (excretion) प्रक्रियाओं के बारे में जानकारी दी गई है। मेपेरिडाइन हाइड्रोक्लोराइड के रासायनिक गुणों या गलनांक का कोई उल्लेख नहीं है।","दिए गए संदर्भ के आधार पर, मैं इस प्रश्न का उत्तर नहीं दे सकता। संदर्भ में **मेपिवाकेन हाइड्रोक्लोराइड** (एक स्थानीय संवेदनाहारी) के बारे में जानकारी है, न कि मेपरिडीन हाइड्रोक्लोराइड के बारे में। ये दो अलग-अलग दवाएं हैं।

संदर्भ में मेपिवाकेन हाइड्रोक्लोराइड का वर्णन ""एक सफेद, क्रिस्टलीय गंधहीन पाउडर, पानी में घुलनशील"" के रूप में किया गया है, लेकिन इसके पिघलने बिंदु के बारे में जानकारी नहीं दी गई है। इसके अतिरिक्त, दिए गए पाठ में मेपरिडीन हाइड्रोक्लोराइड के बारे में कोई जानकारी शामिल नहीं है।

मेपरिडीन हाइड्रोक्लोराइड के गलनांक के बारे में आपके प्रश्न का उत्तर देने के लिए, मुझे विशेष रूप से उस दवा के बारे में दस्तावेज़ तक पहुंच की आवश्यकता होगी।",7.440096855163574,7.797439336776733,0.04041695594787598,0.5375514030456543,7.399679899215698,7.259887933731079,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड की रासायनिक संरचना क्या है?,hindi,What is the chemical structure of meperidine hydrochloride?,". It has the following structural formula: Codeine phosphate (7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1)(salt) hemihydrate) is an opioid agonist. It has the following structural formula: Chemical structure of Butalbital Chemical structure of Acetaminophen Chemical structure of Caffeine Chemical structure of Codeine Phosphate Inactive Ingredients: black iron oxide, colloidal silicon dioxide, FD&C Blue #1, gelatin, magnesium stearate, pregelatinized corn starch, and titanium dioxide.

. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure","There is no information about the chemical structure of **Meperidine Hydrochloride** in the reference provided.

The reference mentions only the chemical structures of the following compounds:
- Codeine Phosphate
- Butalbital
- Acetaminophen
- Caffeine
- **Mepivacaine Hydrochloride** – which is a local anesthetic

Please note that mepivacaine and meperidine are two different medicines. If you require information on the chemical structure of meperidine hydrochloride, please consult appropriate medical sources.","Based on the provided context, I cannot answer your question about **meperidine hydrochloride** because the context only contains information about **mepivacaine hydrochloride**, which is a different medication.

The context describes mepivacaine hydrochloride as:
- Chemical name: 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride
- Molecular formula: C₁₅H₂₂N₂O·HCl
- An amide-type local anesthetic

Meperidine and mepivacaine are two distinct drugs with different chemical structures and uses. If you need information about meperidine hydrochloride specifically, you would need to consult a different source.",". It has the following structural formula: Codeine phosphate (7,8-Didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1)(salt) hemihydrate) is an opioid agonist. It has the following 
---
. In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C ","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition ",Healthcare assistant prompt,"प्रदान किए गए संदर्भ में **मेपेरिडाइन हाइड्रोक्लोराइड** (Meperidine Hydrochloride) की रासायनिक संरचना के बारे में कोई जानकारी नहीं है।

संदर्भ में केवल निम्नलिखित यौगिकों की रासायनिक संरचनाओं का उल्लेख है:
- कोडीन फॉस्फेट (Codeine Phosphate)
- ब्यूटालबिटल (Butalbital)
- एसिटामिनोफेन (Acetaminophen)
- कैफीन (Caffeine)
- **मेपिवाकेन हाइड्रोक्लोराइड** (Mepivacaine Hydrochloride) - जो एक स्थानीय संवेदनाहारी है

कृपया ध्यान दें कि मेपिवाकेन और मेपेरिडाइन दो अलग-अलग दवाएं हैं। यदि आपको मेपेरिडाइन हाइड्रोक्लोराइड की रासायनिक संरचना की जानकारी चाहिए, तो कृपया उचित चिकित्सा स्रोतों से परामर्श करें।","दिए गए संदर्भ के आधार पर, मैं **मेपरिडीन हाइड्रोक्लोराइड** के बारे में आपके प्रश्न का उत्तर नहीं दे सकता क्योंकि संदर्भ में केवल **मेपिवाकेन हाइड्रोक्लोराइड** के बारे में जानकारी है, जो एक अलग दवा है।

संदर्भ मेपिवाकेन हाइड्रोक्लोराइड का वर्णन इस प्रकार करता है:
- रासायनिक नाम: 2-पाइपरिडीनकार्बोक्सामाइड, एन-(2,6-डाइमिथाइलफिनाइल)-1-मिथाइल-, मोनोहाइड्रोक्लोराइड
- आणविक सूत्र: C₁₅H₂₂N₂O·HCl
- एक एमाइड-प्रकार का स्थानीय संवेदनाहारी

मेपरिडीन और मेपिवाकेन अलग-अलग रासायनिक संरचना और उपयोग वाली दो अलग-अलग दवाएं हैं। यदि आपको विशेष रूप से मेपरिडीन हाइड्रोक्लोराइड के बारे में जानकारी चाहिए, तो आपको एक अलग स्रोत से परामर्श लेना होगा।",8.97840929031372,7.854937553405762,0.04967689514160156,0.5324902534484863,8.92873239517212,7.322447299957275,claude-sonnet-4-5-20250929,True
मपेरीडाइन हाइड्रोक्लोराइड का नारकोटिक एनाल्जेसिक के रूप में क्या भूमिका है?,hindi,What is the role of meperidine hydrochloride as a narcotic analgesic?,". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency and toxicity of the metabolites relative to bupropion have not been fully characterized. However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one-half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion. This may be of clinical importance because the plasma concentrations of the metabolites are as high as or higher than those of bupropion

. The formation of 4’-hydroxy- diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuronidation mediated by UGT2B7 and oxidation mediated by CPY2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac. In patients with renal dysfunction, peak concentrations of metabolites 4'-hydroxy- and 5-hydroxy-diclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects. Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine

. The formation of 4’-hydroxy- diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuronidation mediated by UGT2B7 and oxidation mediated by CPY2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac. In patients with renal dysfunction, peak concentrations of metabolites 4'-hydroxy- and 5-hydroxy-diclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects. Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Meperidine hydrochloride is a narcotic analgesic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation. There is some evidence which suggests that meperidine may produce less smooth muscle spasm, constipation and depression of the cough reflex than equianalgesic doses of morphine. Meperidine, in 60 to 80 mg parenteral doses, is approximately equivalent in analgesic effect to 10 mg of morphine. The onset of action is slightly more rapid than with morphine, and the duration of action is slightly shorter. Meperidine is significantly less effective by the oral than by the parenteral route, but the exact ratio of oral to parenteral effectiveness is unknown. In clinical studies, changes in several pharmacokinetic parameters with increasing age have been observed

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Meperidine hydrochloride is a narcotic analgesic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation. There is some evidence which suggests that meperidine may produce less smooth muscle spasm, constipation and depression of the cough reflex than equianalgesic doses of morphine. Meperidine, in 60 to 80 mg parenteral doses, is approximately equivalent in analgesic effect to 10 mg of morphine. The onset of action is slightly more rapid than with morphine, and the duration of action is slightly shorter. Meperidine is significantly less effective by the oral than by the parenteral route, but the exact ratio of oral to parenteral effectiveness is unknown. In clinical studies, changes in several pharmacokinetic parameters with increasing age have been observed

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure","The information provided does not contain any details about Meperidine Hydrochloride. 

The presented material contains only information about the metabolism of the drugs Bupropion and Diclofenac and their interaction with cytochrome P450 enzymes.

To give an accurate answer regarding the role of meperidine hydrochloride as a narcotic analgesic, I would need information related to this specific drug.","Based on the provided FDA medical information, meperidine hydrochloride serves as a narcotic analgesic with the following key roles:

## Primary Therapeutic Actions:
1. **Analgesia** (pain relief) - the principal therapeutic value
2. **Sedation** - secondary therapeutic benefit

## Mechanism and Effects:
Meperidine hydrochloride has multiple actions qualitatively similar to morphine, primarily affecting:
- The central nervous system
- Organs composed of smooth muscle

## Clinical Advantages:
Compared to equianalgesic doses of morphine, meperidine may produce:
- Less smooth muscle spasm
- Less constipation
- Less depression of the cough reflex

## Potency and Characteristics:
- **Dose equivalence**: 60-80 mg of parenteral meperidine is approximately equivalent to 10 mg of morphine in analgesic effect
- **Onset**: Slightly more rapid than morphine
- **Duration**: Slightly shorter than morphine
- **Route effectiveness**: Significantly less effective by oral route compared to parenteral (intramuscular, subcutaneous, or slow intravenous) administration

In summary, meperidine hydrochloride functions as a narcotic analgesic primarily for pain relief and sedation, offering some potential advantages over morphine in terms of side effects while maintaining comparable analgesic efficacy.",". In vitro findings suggest that cytochrome P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 isoenzymes are not involved in the formati
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion
---
. The formation of 4’-hydroxy- diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuro
---
. The formation of 4’-hydroxy- diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuro","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Meperidine hydrochloride is a narcotic analgesic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the 
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Meperidine hydrochloride is a narcotic analgesic with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont",Healthcare assistant prompt,"प्रदान की गई जानकारी में मेपेरीडाइन हाइड्रोक्लोराइड (Meperidine Hydrochloride) के बारे में कोई विवरण नहीं है। 

दी गई सामग्री में केवल ब्यूप्रोपियन (Bupropion) और डाइक्लोफेनाक (Diclofenac) दवाओं के मेटाबोलिज्म और उनके साइटोक्रोम P450 एंजाइम्स के साथ संबंध के बारे में जानकारी है।

मेपेरीडाइन हाइड्रोक्लोराइड की नारकोटिक एनाल्जेसिक के रूप में भूमिका के बारे में सटीक उत्तर देने के लिए, मुझे इस विशिष्ट दवा से संबंधित जानकारी की आवश्यकता होगी।","प्रदान की गई एफडीए चिकित्सा जानकारी के आधार पर, मेपरिडीन हाइड्रोक्लोराइड निम्नलिखित प्रमुख भूमिकाओं के साथ एक मादक दर्दनाशक के रूप में कार्य करता है:

## प्राथमिक चिकित्सीय क्रियाएँ:
1. **एनाल्जेसिया** (दर्द से राहत) - प्रमुख चिकित्सीय मूल्य
2. **शामक** - द्वितीयक चिकित्सीय लाभ

## तंत्र और प्रभाव:
मेपरिडीन हाइड्रोक्लोराइड में मॉर्फिन के समान गुणात्मक रूप से कई क्रियाएं होती हैं, जो मुख्य रूप से प्रभावित करती हैं:
- केंद्रीय तंत्रिका तंत्र
- चिकनी मांसपेशियों से बने अंग

## नैदानिक लाभ:
मॉर्फिन की समान एनाल्जेसिक खुराक की तुलना में, मेपरिडीन का उत्पादन हो सकता है:
- कम चिकनी मांसपेशियों की ऐंठन
-कब्ज कम होती है
- कफ प्रतिवर्त का कम अवसाद

## सामर्थ्य और विशेषताएँ:
- **खुराक तुल्यता**: 60-80 मिलीग्राम पैरेंट्रल मेपरिडीन एनाल्जेसिक प्रभाव में लगभग 10 मिलीग्राम मॉर्फिन के बराबर है
- **शुरुआत**: मॉर्फिन से थोड़ा अधिक तेज़
- **अवधि**: मॉर्फिन से थोड़ा कम
- **मार्ग प्रभावशीलता**: पैरेंट्रल (इंट्रामस्क्युलर, चमड़े के नीचे, या धीमी अंतःशिरा) प्रशासन की तुलना में मौखिक मार्ग से काफी कम प्रभावी

संक्षेप में, मेपरिडीन हाइड्रोक्लोराइड मुख्य रूप से दर्द से राहत और बेहोश करने के लिए एक मादक दर्दनाशक के रूप में कार्य करता है, जो तुलनीय एनाल्जेसिक प्रभावकारिता को बनाए रखते हुए साइड इफेक्ट के मामले में मॉर्फिन पर कुछ संभावित लाभ प्रदान करता है।",8.524229049682617,10.536610126495361,0.04271817207336426,0.49581074714660645,8.481510877609253,10.040799379348755,claude-sonnet-4-5-20250929,True
मेपेरिडाइन हाइड्रोक्लोराइड इंजेक्शन के लिए उपलब्ध सांद्रता क्या हैं?,hindi,What are the available concentrations for meperidine hydrochloride injection?,". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

. An in vitro study indicated that buspirone did not displace highly protein-bound drugs such as phenytoin, warfarin, and propranolol from plasma protein, and that buspirone may displace digoxin. Buspirone is metabolized primarily by oxidation, which in vitro has been shown to be mediated by cytochrome P450 3A4 (CYP3A4). (See PRECAUTIONS, Drug Interactions section.) Several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP), are produced. In animal models predictive of anxiolytic potential, 1-PP has about one quarter of the activity of buspirone, but is present in up to 20-fold greater amounts

DESCRIPTION: DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste. It is soluble in water, chloroform, and methanol. Verapamil hydrochloride is not chemically related to other cardioactive drugs. Inactive ingredients include anhydrous lactose, corn starch, hypromellose 2910, magnesium stearate, microcrystalline cellulose, polacrilin potassium, and polyethylene glycol 400. In addition the following coloring agents are used: FD&C Yellow No

DESCRIPTION: DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste. It is soluble in water, chloroform, and methanol. Verapamil hydrochloride is not chemically related to other cardioactive drugs. Inactive ingredients include anhydrous lactose, corn starch, hypromellose 2910, magnesium stearate, microcrystalline cellulose, polacrilin potassium, and polyethylene glycol 400. In addition the following coloring agents are used: FD&C Yellow No

. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users. First-pass metabolism of EE involves formation of EE-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed EE by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of EE hydroxylation. Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation. Excretion About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates","DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

. Solutions which are discolored or which contain particulate matter should not be administered. Recommended Concentrations and Doses of Mepivacaine Hydrochloride Procedure Concentration Total Dose Comments mL mg Cervical, brachial, intercostal, 1% 5−40 50−400 Pudendal block: one half of total dose injected each side. pudendal nerve block 2% 5−20 100−400 Transvaginal block (paracervical plus pudendal) 1% up to 30 (both sides) up to 300 (both sides) One half of total dose injected each side. See PRECAUTIONS . Paracervical block 1% up to 20 (both sides) up to 200 (both sides) One half of total dose injected each side. This is maximum recommended dose per 90-minute period in obstetrical and non-obstetrical patients. Inject slowly, 5 minutes between sides. See PRECAUTIONS . Caudal and Epidural block 1% 1.5% 15−30 10−25 150−300 150−375 Dosage forms listed as POLOCAINE-MPF (Mepivacaine HCl injection, USP) are single-dose solutions which do not contain a preservative

. For specific techniques and procedures, refer to standard textbooks. The recommended single adult dose (or the total of a series of doses given in one procedure) of mepivacaine hydrochloride for unsedated, healthy, normal-sized individuals should not usually exceed 400 mg. The recommended dosage is based on requirements for the average adult and should be reduced for elderly or debilitated patients. While maximum doses of 7 mg/kg (550 mg) have been administered without adverse effect, these are not recommended, except in exceptional circumstances and under no circumstances should the administration be repeated at intervals of less than 1 1 / 2 hours. The total dose for any 24-hour period should not exceed 1,000 mg because of a slow accumulation of the anesthetic or its derivatives or slower than normal metabolic degradation or detoxification with repeat administration. (See CLINICAL PHARMACOLOGY and PRECAUTIONS ). Pediatric patients tolerate the local anesthetic as well as adults","The information provided does not contain any details about **Meperidine Hydrochloride** Injection.

The given material contains information only about **Mepivacaine hydrochloride**, which is a local anesthetic. Mepivacaine is available in the following concentrations:

- 1% (10 mg/mL)
- 1.5% (15 mg/mL)
- 2% (20 mg/mL)

Please note that mepivacaine and meperidine are two different medicines. If you need information about meperidine hydrochloride, please consult other sources.","Based on the provided context, **meperidine hydrochloride injection** is available in the following concentrations:

- **25 mg/mL**
- **50 mg/mL**
- **75 mg/mL**
- **100 mg/mL**

These concentrations are provided in DOSETTE vials as a sterile solution for intramuscular, subcutaneous, or slow intravenous use as a narcotic analgesic.",". Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
. An in vitro study indicated that buspirone did not displace highly protein-bound drugs such as phenytoin, warfarin, and propranolol from plasma protein, and that buspirone may displace digoxin. Busp
---
DESCRIPTION: DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 
---
DESCRIPTION: DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 
---
. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for ","DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
. Solutions which are discolored or which contain particulate matter should not be administered. Recommended Concentrations and Doses of Mepivacaine Hydrochloride Procedure Concentration Total Dose Co
---
. For specific techniques and procedures, refer to standard textbooks. The recommended single adult dose (or the total of a series of doses given in one procedure) of mepivacaine hydrochloride for uns",Healthcare assistant prompt,"प्रदान की गई जानकारी में **मेपेरिडाइन हाइड्रोक्लोराइड** इंजेक्शन के बारे में कोई विवरण नहीं है।

दी गई सामग्री में केवल **मेपिवाकेन हाइड्रोक्लोराइड** (Mepivacaine hydrochloride) के बारे में जानकारी है, जो एक स्थानीय संवेदनाहारी (local anesthetic) है। मेपिवाकेन निम्नलिखित सांद्रता में उपलब्ध है:

- 1% (10 mg/mL)
- 1.5% (15 mg/mL)
- 2% (20 mg/mL)

कृपया ध्यान दें कि मेपिवाकेन और मेपेरिडाइन दो अलग-अलग दवाएं हैं। यदि आपको मेपेरिडाइन हाइड्रोक्लोराइड के बारे में जानकारी चाहिए, तो कृपया अन्य स्रोतों से परामर्श करें।","दिए गए संदर्भ के आधार पर, **मेपरिडीन हाइड्रोक्लोराइड इंजेक्शन** निम्नलिखित सांद्रता में उपलब्ध है:

- **25 मिलीग्राम/एमएल**
- **50 मिलीग्राम/एमएल**
- **75 मिलीग्राम/एमएल**
- **100 मिलीग्राम/एमएल**

ये सांद्रता डोसेट शीशियों में एक मादक दर्दनाशक के रूप में इंट्रामस्क्युलर, चमड़े के नीचे, या धीमी अंतःशिरा उपयोग के लिए एक बाँझ समाधान के रूप में प्रदान की जाती है।",8.563524723052979,6.803988933563232,0.04163384437561035,0.5739362239837646,8.521890878677368,6.230052709579468,claude-sonnet-4-5-20250929,True
स्थानीय एनेस्थेटिक्स में प्लाज्मा सांद्रता और दवा बाइंडिंग के बीच क्या संबंध है?,hindi,What is the relationship between plasma concentrations and drug binding in local anesthetics?,". Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs are summarized in Figure 1. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Specific Populations Effect of specific populations on the pharmacokinetics of LBQ657 and valsartan are shown in Figure 2. Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations Note: Child-Pugh Classification was used for hepatic impairment. Pediatric Patients: The pharmacokinetics of ENTRESTO were evaluated in pediatric heart failure patients 1 to less than 18 years old administered oral doses of 0.8 mg/kg and 3.1 mg/kg of ENTRESTO. Pharmacokinetic data indicated that exposure to ENTRESTO in pediatric and adult patients is similar. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations

. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs are summarized in Figure 1. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Specific Populations Effect of specific populations on the pharmacokinetics of LBQ657 and valsartan are shown in Figure 2. Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations Note: Child-Pugh Classification was used for hepatic impairment. Pediatric Patients: The pharmacokinetics of ENTRESTO were evaluated in pediatric heart failure patients 1 to less than 18 years old administered oral doses of 0.8 mg/kg and 3.1 mg/kg of ENTRESTO. Pharmacokinetic data indicated that exposure to ENTRESTO in pediatric and adult patients is similar. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations

. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs are summarized in Figure 1. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Specific Populations Effect of specific populations on the pharmacokinetics of LBQ657 and valsartan are shown in Figure 2. Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations Note: Child-Pugh Classification was used for hepatic impairment. Pediatric Patients: The pharmacokinetics of ENTRESTO were evaluated in pediatric heart failure patients 1 to less than 18 years old administered oral doses of 0.8 mg/kg and 3.1 mg/kg of ENTRESTO. Pharmacokinetic data indicated that exposure to ENTRESTO in pediatric and adult patients is similar. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations

. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs are summarized in Figure 1. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Specific Populations Effect of specific populations on the pharmacokinetics of LBQ657 and valsartan are shown in Figure 2. Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations Note: Child-Pugh Classification was used for hepatic impairment. Pediatric Patients: The pharmacokinetics of ENTRESTO were evaluated in pediatric heart failure patients 1 to less than 18 years old administered oral doses of 0.8 mg/kg and 3.1 mg/kg of ENTRESTO. Pharmacokinetic data indicated that exposure to ENTRESTO in pediatric and adult patients is similar. Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations

. Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined. Pharmacodynamics Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the antianginal efficacy of continuously delivered nitrates. In the large majority of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their antianginal efficacy been restored",". Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacaine is approximately 75% bound to plasma proteins. The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation. Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient

DOSAGE AND ADMINISTRATION: DOSAGE AND ADMINISTRATION The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of mepivacaine hydrochloride should be reduced for elderly and debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional doses should be used when feasible. For specific techniques and procedures, refer to standard textbooks

. Local anesthetic solutions containing antimicrobial preservatives (ie, those supplied in multiple-dose vials) should not be used for epidural or caudal anesthesia because safety has not been established with regard to intrathecal injection, either intentionally or inadvertently, of such preservatives. It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection. Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics. Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur

. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from human adults: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2′,6′-pipecoloxylidide). Mepivacaine does not ordinarily produce irritation or tissue damage, and does not cause methemoglobinemia when administered in recommended doses and concentrations.

. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer","The information provided does not contain any details regarding the relationship between plasma concentrations and drug binding of local anesthetics.

The given material contains information only about the following medicines:
1. **ENTRESTO** - which is a medicine for heart failure
2. **Organic Nitrates** - which are used for angina

If you need specific information about local anesthetics, please consult relevant medical sources.","Based on the provided medical information, the relationship between plasma concentrations and drug binding in local anesthetics is **inversely proportional**:

**""Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.""**

This means:
- **Lower plasma concentrations** → **Higher percentage of protein binding**
- **Higher plasma concentrations** → **Lower percentage of protein binding**

This relationship is clinically significant because only the free (unbound) drug is pharmacologically active and available for:
- Placental transfer (in pregnant patients)
- Distribution to tissues
- Therapeutic effect

The context also notes that mepivacaine specifically is approximately 75% bound to plasma proteins, and that this protein binding affects the fetal/maternal ratios during placental transfer, as only the unbound drug can cross the placenta.",". Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs
---
. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs
---
. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs
---
. Effect of ENTRESTO on Co-administered Drugs: In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. The effects of ENTRESTO on the pharmacokinetics of coadministered drugs
---
. Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined. Pharmacodynamics Dosing regimens for mo",". Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacain
---
DOSAGE AND ADMINISTRATION: DOSAGE AND ADMINISTRATION The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, th
---
. Local anesthetic solutions containing antimicrobial preservatives (ie, those supplied in multiple-dose vials) should not be used for epidural or caudal anesthesia because safety has not been establi
---
. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been ide
---
. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du",Healthcare assistant prompt,"प्रदान की गई जानकारी में स्थानीय एनेस्थेटिक्स (local anesthetics) में प्लाज्मा सांद्रता और दवा बाइंडिंग के बीच संबंध के बारे में कोई विवरण नहीं है।

दी गई सामग्री में केवल निम्नलिखित दवाओं की जानकारी है:
1. **ENTRESTO** - जो हृदय विफलता (heart failure) की दवा है
2. **ऑर्गेनिक नाइट्रेट्स** - जो एनजाइना (angina) के लिए उपयोग की जाती हैं

यदि आपको स्थानीय एनेस्थेटिक्स के बारे में विशिष्ट जानकारी चाहिए, तो कृपया उससे संबंधित चिकित्सा स्रोतों से परामर्श करें।","प्रदान की गई चिकित्सा जानकारी के आधार पर, स्थानीय एनेस्थेटिक्स में प्लाज्मा सांद्रता और दवा बाइंडिंग के बीच संबंध **विपरीत आनुपातिक** है:

**""आम तौर पर, दवा की प्लाज्मा सांद्रता जितनी कम होगी, प्लाज्मा से बंधी दवा का प्रतिशत उतना अधिक होगा।""**

इसका मतलब है:
- **कम प्लाज्मा सांद्रता** → **प्रोटीन बाइंडिंग का उच्च प्रतिशत**
- **उच्च प्लाज्मा सांद्रता** → **प्रोटीन बाइंडिंग का कम प्रतिशत**

यह संबंध चिकित्सकीय रूप से महत्वपूर्ण है क्योंकि केवल मुफ़्त (अनबाउंड) दवा ही औषधीय रूप से सक्रिय है और इसके लिए उपलब्ध है:
- प्लेसेंटल स्थानांतरण (गर्भवती रोगियों में)
- ऊतकों में वितरण
- उपचारात्मक प्रभाव

संदर्भ यह भी नोट करता है कि मेपिवैकेन विशेष रूप से लगभग 75% प्लाज्मा प्रोटीन से बंधा होता है, और यह प्रोटीन बंधन प्लेसेंटल ट्रांसफर के दौरान भ्रूण/मातृ अनुपात को प्रभावित करता है, क्योंकि केवल अनबाउंड दवा ही प्लेसेंटा को पार कर सकती है।",7.668999671936035,8.368978023529053,0.03843235969543457,0.5329670906066895,7.630567312240601,7.836010932922363,claude-sonnet-4-5-20250929,True
ज़ोलेड्रोनिक एसिड इंजेक्शन के संभावित गुर्दे संबंधी दुष्प्रभाव क्या हैं?,hindi,What are the possible renal side effects of zoledronic acid injection?,"ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Cardiac disorders: Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE ). Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking Hydroxychloroquine sulfate tablets (see OVERDOSAGE and DRUG INTERACTIONS )

ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis. When fludrocortisone is used in the small dosages recommended, the glucocorticoid side effects often seen with cortisone and its derivatives are not usually a problem; however the following untoward effects should be kept in mind, particularly when fludrocortisone is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. Musculoskeletal – muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, and spontaneous fractures

ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis. When fludrocortisone is used in the small dosages recommended, the glucocorticoid side effects often seen with cortisone and its derivatives are not usually a problem; however the following untoward effects should be kept in mind, particularly when fludrocortisone is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. Musculoskeletal – muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, and spontaneous fractures

ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis. When fludrocortisone is used in the small dosages recommended, the glucocorticoid side effects often seen with cortisone and its derivatives are not usually a problem; however the following untoward effects should be kept in mind, particularly when fludrocortisone is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. Musculoskeletal – muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, and spontaneous fractures

ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis. When fludrocortisone is used in the small dosages recommended, the glucocorticoid side effects often seen with cortisone and its derivatives are not usually a problem; however the following untoward effects should be kept in mind, particularly when fludrocortisone is used over a prolonged period of time or in conjunction with cortisone or a similar glucocorticoid. Musculoskeletal – muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones, and spontaneous fractures",". The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [ see Warnings and Precautions ( 5 ) and Dosage and Administration ( 2 ) ]. The most frequently observed adverse events were fever, nausea, constipation, anemia and dyspnea. (see Table 3 ). Table 3 provides adverse events that were reported by 10% or more of the 189 patients treated with Zoledronic Acid Injection 4 mg or Pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug. Table 3: Percentage of Patients with Adverse Events ≥10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System Zoledronic Acid Injection 4 mg n (%) Pamidronate 90 mg n (%) Patients Studied Total No. of Patients Studied 86 (100) 103 (100) Total No

. The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [ see Warnings and Precautions ( 5 ) and Dosage and Administration ( 2 ) ]. The most frequently observed adverse events were fever, nausea, constipation, anemia and dyspnea. (see Table 3 ). Table 3 provides adverse events that were reported by 10% or more of the 189 patients treated with Zoledronic Acid Injection 4 mg or Pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug. Table 3: Percentage of Patients with Adverse Events ≥10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System Zoledronic Acid Injection 4 mg n (%) Pamidronate 90 mg n (%) Patients Studied Total No. of Patients Studied 86 (100) 103 (100) Total No

. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients with Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine* *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of Zoledronic Acid Injection to 15 minutes

. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients with Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine* *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of Zoledronic Acid Injection to 15 minutes

. Factors predisposing to renal deterioration, such as dehydration or the use of other nephrotoxic drugs, should be identified and managed, if possible. Zoledronic Acid Injection treatment in patients with hypercalcemia of malignancy with severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine greater than 400 μmol/L or greater than 4.5 mg/dL were excluded. Zoledronic Acid Injection treatment is not recommended in patients with bone metastases with severe renal impairment. In the clinical studies, patients with serum creatinine greater than 265 μmol/L or greater than 3.0 mg/dL were excluded and there were only 8 of 564 patients treated with Zoledronic Acid Injection 4 mg by 15-minute infusion with a baseline creatinine greater than 2 mg/dL. Limited pharmacokinetic data exists in patients with creatinine clearance less than 30 mL/min [ see Clinical Pharmacology ( 12.3 ) ]","The information provided does not contain any details about zoledronic acid injection. Only information on adverse reactions of hydroxychloroquine sulphate tablets and fludrocortisone is available in the given reference.

To give you accurate information about the kidney side effects of zoledronic acid injection, I will need specific medical documentation related to this medicine.

Please consult your doctor or pharmacist about possible renal side effects of zoledronic acid.","Based on the FDA medical information provided, the possible renal side effects of zoledronic acid injection include:

**Primary Renal Side Effects:**
1. **Renal toxicity**
2. **Renal failure**
3. **Renal deterioration** (treatment-emergent renal function deterioration)

**Important Safety Information:**

- The incidence of renal toxicity and renal failure has been shown to be **reduced when administered as a 15-minute intravenous infusion** (rather than a shorter infusion time)

- The medication should be administered by intravenous infusion over **no less than 15 minutes** to minimize renal risks

**Risk Factors:**
Factors that may increase the risk of renal deterioration include:
- Dehydration
- Use of other nephrotoxic drugs
- Pre-existing severe renal impairment

**Contraindications and Precautions:**
- Treatment is **not recommended** in patients with bone metastases who have severe renal impairment
- Clinical studies excluded patients with serum creatinine greater than 400 μmol/L (4.5 mg/dL) for hypercalcemia of malignancy
- Clinical studies excluded patients with serum creatinine greater than 265 μmol/L (3.0 mg/dL) for bone metastases
- Limited data exists for patients with creatinine clearance less than 30 mL/min

Healthcare providers should carefully evaluate risks versus benefits and monitor renal function when prescribing zoledronic acid injection.","ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because the
---
ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, co
---
ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, co
---
ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, co
---
ADVERSE REACTIONS: ADVERSE REACTIONS Most adverse reactions are caused by the drug's mineralocorticoid activity (retention of sodium and water) and include hypertension, edema, cardiac enlargement, co",". The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be
---
. The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be
---
. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients wi
---
. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients wi
---
. Factors predisposing to renal deterioration, such as dehydration or the use of other nephrotoxic drugs, should be identified and managed, if possible. Zoledronic Acid Injection treatment in patients",Healthcare assistant prompt,"प्रदान की गई जानकारी में ज़ोलेड्रोनिक एसिड इंजेक्शन के बारे में कोई विवरण नहीं है। दिए गए संदर्भ में केवल हाइड्रोक्सीक्लोरोक्वीन सल्फेट टैबलेट और फ्लूड्रोकोर्टिसोन की प्रतिकूल प्रतिक्रियाओं (adverse reactions) की जानकारी उपलब्ध है।

ज़ोलेड्रोनिक एसिड इंजेक्शन के गुर्दे संबंधी दुष्प्रभावों के बारे में सटीक जानकारी देने के लिए मुझे इस दवा से संबंधित विशिष्ट चिकित्सा दस्तावेज़ों की आवश्यकता होगी।

कृपया अपने डॉक्टर या फार्मासिस्ट से ज़ोलेड्रोनिक एसिड के संभावित गुर्दे संबंधी दुष्प्रभावों के बारे में परामर्श करें।","एफडीए द्वारा प्रदान की गई चिकित्सा जानकारी के आधार पर, ज़ोलेड्रोनिक एसिड इंजेक्शन के संभावित गुर्दे संबंधी दुष्प्रभावों में शामिल हैं:

**प्राथमिक गुर्दे संबंधी दुष्प्रभाव:**
1. **गुर्दे की विषाक्तता**
2. **गुर्दे की विफलता**
3. **गुर्दे की खराबी** (उपचार-आकस्मिक गुर्दे की कार्यप्रणाली में गिरावट)

**महत्वपूर्ण सुरक्षा सूचना:**

- गुर्दे की विषाक्तता और गुर्दे की विफलता की घटनाओं को **15 मिनट के अंतःशिरा जलसेक के रूप में प्रशासित करने पर कम होना** दिखाया गया है (कम जलसेक समय के बजाय)

- गुर्दे के जोखिम को कम करने के लिए दवा को कम से कम 15 मिनट तक अंतःशिरा जलसेक द्वारा प्रशासित किया जाना चाहिए।

**जोखिम कारक:**
गुर्दे की खराबी के जोखिम को बढ़ाने वाले कारकों में शामिल हैं:
- निर्जलीकरण
- अन्य नेफ्रोटॉक्सिक दवाओं का उपयोग
- पहले से मौजूद गंभीर गुर्दे की हानि

**विरोधाभास और सावधानियां:**
- अस्थि मेटास्टेस वाले उन रोगियों में उपचार की **अनुशंसा नहीं की जाती** है, जिनमें गंभीर गुर्दे की हानि होती है
- नैदानिक ​​अध्ययनों में 400 μmol/L (4.5 mg/dL) से अधिक सीरम क्रिएटिनिन वाले रोगियों को दुर्दमता के हाइपरकैल्सीमिया के लिए बाहर रखा गया है।
- नैदानिक ​​अध्ययनों में अस्थि मेटास्टेस के लिए 265 μmol/L (3.0 mg/dL) से अधिक सीरम क्रिएटिनिन वाले रोगियों को बाहर रखा गया
- 30 एमएल/मिनट से कम क्रिएटिनिन क्लीयरेंस वाले रोगियों के लिए सीमित डेटा मौजूद है

ज़ोलेड्रोनिक एसिड इंजेक्शन निर्धारित करते समय स्वास्थ्य सेवा प्रदाताओं को जोखिम बनाम लाभ का सावधानीपूर्वक मूल्यांकन करना चाहिए और गुर्दे के कार्य की निगरानी करनी चाहिए।",8.744919300079346,10.264586210250854,0.043244361877441406,0.4989893436431885,8.701674938201904,9.765596866607666,claude-sonnet-4-5-20250929,True
ज़ोलेड्रोनिक एसिड इंजेक्शन के पोस्ट-अप्रूवल उपयोग के दौरान रिपोर्ट की गई प्रतिकूल प्रतिक्रियाएं क्या हैं?,hindi,What are the adverse reactions reported during post-approval use of zoledronic acid injection?,"ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Cardiac disorders: Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE ). Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking Hydroxychloroquine sulfate tablets (see OVERDOSAGE and DRUG INTERACTIONS )

ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post approval use of hydrocodone and acetaminophen tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. Other adverse reactions include: Central Nervous System: Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychological dependence, mood changes. Gastrointestinal System: Constipation. Genitourinary System: Ureteral spasm, spasm of vesical sphincters, and urinary retention. Special Senses: Cases of hearing impairment or permanent loss have been reported predominately in patients with chronic overdose

. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of indomethacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and Appendages: Exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and fixed drug eruption (FDE).

. Laboratory Tests: Mild to moderate elevations of ALT, LDH, alkaline phosphatase, BUN and creatinine have been noted. The relationship of these abnormalities to glipizide is uncertain. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of glipizide extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure

ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-marketing experience. The relationship of some of these events to Amnesteem therapy is unknown. Many of the side effects and adverse reactions seen in patients receiving Amnesteem are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage and eyes). Dose Relationship Cheilitis and hypertriglyceridemia are usually dose related. Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy (see WARNINGS and ADVERSE REACTIONS )","adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with Zoledronic Acid Injection 4 mg than with pamidronate 90 mg and occurred with a frequency of greater than or equal to 5% but less than 10%

adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with Zoledronic Acid Injection 4 mg than with pamidronate 90 mg and occurred with a frequency of greater than or equal to 5% but less than 10%

. Less common adverse events reported more often with Zoledronic Acid Injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the Zoledronic Acid Injection 4 mg group compared with 9% in the pamidronate group. Decreased appetite was reported in slightly more patients in the Zoledronic Acid Injection 4 mg group (13%) compared with the Pamidronate (9%) and placebo (10%) groups, but the clinical significance of these small differences is not clear. Renal Toxicity In the bone metastases trials, renal deterioration was defined as an increase of 0.5 mg/dL for patients with normal baseline creatinine (less than 1.4 mg/dL) or an increase of 1.0 mg /dL for patients with an abnormal baseline creatinine (greater than or equal to 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 )

. Less common adverse events reported more often with Zoledronic Acid Injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the Zoledronic Acid Injection 4 mg group compared with 9% in the pamidronate group. Decreased appetite was reported in slightly more patients in the Zoledronic Acid Injection 4 mg group (13%) compared with the Pamidronate (9%) and placebo (10%) groups, but the clinical significance of these small differences is not clear. Renal Toxicity In the bone metastases trials, renal deterioration was defined as an increase of 0.5 mg/dL for patients with normal baseline creatinine (less than 1.4 mg/dL) or an increase of 1.0 mg /dL for patients with an abnormal baseline creatinine (greater than or equal to 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 )

ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Cardiac disorders: Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE ). Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking Hydroxychloroquine sulfate tablets (see OVERDOSAGE and DRUG INTERACTIONS )","I'm sorry, but there is no information about Zoledronic Acid Injection in the reference provided.

The reference given contains information on adverse reactions only for the following medicines:
- Hydroxychloroquine sulphate
- Hydrocodone and Acetaminophen
- Indomethacin
- Glipizide
- Amnesteem

To get accurate information about zoledronic acid injection, please consult your doctor or pharmacist.","Based on the provided context, the information about post-approval adverse reactions refers to **Hydroxychloroquine sulfate tablets**, not zoledronic acid injection.

The context provided discusses adverse events from clinical trials of zoledronic acid injection (comparing it to pamidronate), including:
- Decreased weight (16% vs 9% with pamidronate)
- Decreased appetite (13% vs 9% with pamidronate)
- Renal deterioration/toxicity

However, the section specifically labeled ""post-approval use"" adverse reactions describes hydroxychloroquine sulfate tablets, which is a completely different medication.

The context does not contain information about post-approval (post-marketing) adverse reactions specifically for zoledronic acid injection. To answer your question accurately, I would need access to the post-marketing surveillance data or prescribing information section that specifically addresses post-approval adverse reactions for zoledronic acid.","ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because the
---
ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post approval use of hydrocodone and acetaminophen tablets. Because these reactions are reported volunt
---
. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of indomethacin. Because these reactions are reported voluntarily from a population of uncer
---
. Laboratory Tests: Mild to moderate elevations of ALT, LDH, alkaline phosphatase, BUN and creatinine have been noted. The relationship of these abnormalities to glipizide is uncertain. 6.2 Postmarket
---
ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-m","adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with Zoledronic Acid Injection 4 mg than with pamidronate 90 mg and occu
---
adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with Zoledronic Acid Injection 4 mg than with pamidronate 90 mg and occu
---
. Less common adverse events reported more often with Zoledronic Acid Injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the Zoledronic Acid Injection 
---
. Less common adverse events reported more often with Zoledronic Acid Injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the Zoledronic Acid Injection 
---
ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because the",Healthcare assistant prompt,"मुझे खेद है, लेकिन प्रदान किए गए संदर्भ में ज़ोलेड्रोनिक एसिड इंजेक्शन (Zoledronic Acid Injection) के बारे में कोई जानकारी नहीं है।

दिए गए संदर्भ में केवल निम्नलिखित दवाओं की प्रतिकूल प्रतिक्रियाओं की जानकारी है:
- हाइड्रोक्सीक्लोरोक्वीन सल्फेट (Hydroxychloroquine sulfate)
- हाइड्रोकोडोन और एसिटामिनोफेन (Hydrocodone and Acetaminophen)
- इंडोमेथासिन (Indomethacin)
- ग्लिपिज़ाइड (Glipizide)
- एम्नेस्टीम (Amnesteem)

ज़ोलेड्रोनिक एसिड इंजेक्शन के बारे में सटीक जानकारी प्राप्त करने के लिए, कृपया अपने चिकित्सक या फार्मासिस्ट से परामर्श करें।","दिए गए संदर्भ के आधार पर, अनुमोदन के बाद की प्रतिकूल प्रतिक्रियाओं के बारे में जानकारी **हाइड्रॉक्सीक्लोरोक्वीन सल्फेट टैबलेट** को संदर्भित करती है, ज़ोलेड्रोनिक एसिड इंजेक्शन को नहीं।

प्रदान किया गया संदर्भ ज़ोलेड्रोनिक एसिड इंजेक्शन के नैदानिक ​​परीक्षणों से प्रतिकूल घटनाओं पर चर्चा करता है (इसकी तुलना पामिड्रोनेट से की जाती है), जिसमें शामिल हैं:
- वज़न में कमी (पामिड्रोनेट के साथ 16% बनाम 9%)
- भूख में कमी (पामिड्रोनेट के साथ 13% बनाम 9%)
- गुर्दे की खराबी/विषाक्तता

हालाँकि, विशेष रूप से ""अनुमोदन के बाद उपयोग"" प्रतिकूल प्रतिक्रियाओं का लेबल वाला अनुभाग हाइड्रोक्सीक्लोरोक्वीन सल्फेट टैबलेट का वर्णन करता है, जो एक पूरी तरह से अलग दवा है।

संदर्भ में विशेष रूप से ज़ोलेड्रोनिक एसिड इंजेक्शन के लिए अनुमोदन के बाद (विपणन के बाद) प्रतिकूल प्रतिक्रियाओं के बारे में जानकारी शामिल नहीं है। आपके प्रश्न का सटीक उत्तर देने के लिए, मुझे पोस्ट-मार्केटिंग निगरानी डेटा या प्रिस्क्राइबिंग सूचना अनुभाग तक पहुंच की आवश्यकता होगी जो विशेष रूप से ज़ोलेड्रोनिक एसिड के लिए अनुमोदन के बाद की प्रतिकूल प्रतिक्रियाओं को संबोधित करता है।",8.895303726196289,8.4608473777771,0.037361860275268555,0.48672914505004883,8.85794186592102,7.974118232727051,claude-sonnet-4-5-20250929,True
